{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"WO_2010_138490_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"019-041-955-500-923"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":22718,"type":"PATENT","title":"Citing Vanderbilt Univ publications","description":"Patent documents citing scholarly work of Vanderbilt Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":27696,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:37:25Z","updated":"2017-08-07T04:37:25Z","lastEventDate":"2017-08-07T04:37:25Z"},{"id":22721,"type":"PATENT","title":"Citing CNRS publications","description":"Patent documents citing scholarly work of CNRS","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":129822,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:38:15Z","updated":"2017-08-07T04:38:15Z","lastEventDate":"2017-08-07T04:38:15Z"},{"id":22728,"type":"PATENT","title":"Citing UC Davis publications","description":"Patent documents citing scholarly work of UC Davis","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":34174,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:41:48Z","updated":"2017-08-07T04:41:48Z","lastEventDate":"2017-08-07T04:41:48Z"},{"id":22729,"type":"PATENT","title":"Citing UC Los Angeles publications","description":"Patent documents citing scholarly work of UC Los Angeles","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":73948,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:42:18Z","updated":"2017-08-07T04:42:18Z","lastEventDate":"2017-08-07T04:42:18Z"},{"id":22739,"type":"PATENT","title":"Citing KU Leuven publications","description":"Patent documents citing scholarly work of KU Leuven","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":30113,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:46:44Z","updated":"2017-08-07T04:46:44Z","lastEventDate":"2017-08-07T04:46:44Z"},{"id":22751,"type":"PATENT","title":"Citing UT Health Science Center publications","description":"Patent documents citing scholarly work of UT Health Science Center","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8794,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:50:40Z","updated":"2017-08-07T04:50:40Z","lastEventDate":"2017-08-07T04:50:40Z"},{"id":22757,"type":"PATENT","title":"Citing Cornell Univ publications","description":"Patent documents citing scholarly work of Cornell Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":60392,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:53:01Z","updated":"2017-08-07T04:53:01Z","lastEventDate":"2017-08-07T04:53:01Z"},{"id":22763,"type":"PATENT","title":"Citing NYU publications","description":"Patent documents citing scholarly work of NYU","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":34711,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:55:15Z","updated":"2017-08-07T04:55:15Z","lastEventDate":"2017-08-07T04:55:15Z"},{"id":22764,"type":"PATENT","title":"Citing Univ Paris Descartes publications","description":"Patent documents citing scholarly work of Univ Paris Descartes","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":10846,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:55:45Z","updated":"2017-08-07T04:55:45Z","lastEventDate":"2017-08-07T04:55:45Z"},{"id":22766,"type":"PATENT","title":"Citing McGill Univ publications","description":"Patent documents citing scholarly work of McGill Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":33777,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:56:02Z","updated":"2017-08-07T04:56:02Z","lastEventDate":"2017-08-07T04:56:02Z"},{"id":22773,"type":"PATENT","title":"Citing Univ Washington publications","description":"Patent documents citing scholarly work of Univ Washington","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":75126,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:58:47Z","updated":"2017-08-07T04:58:47Z","lastEventDate":"2017-08-07T04:58:47Z"},{"id":22779,"type":"PATENT","title":"Citing UBC publications","description":"Patent documents citing scholarly work of UBC","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":34693,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:01:43Z","updated":"2017-08-07T05:01:43Z","lastEventDate":"2017-08-07T05:01:43Z"},{"id":22786,"type":"PATENT","title":"Citing Duke Univ publications","description":"Patent documents citing scholarly work of Duke Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":52418,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:04:02Z","updated":"2017-08-07T05:04:02Z","lastEventDate":"2017-08-07T05:04:02Z"},{"id":22790,"type":"PATENT","title":"Citing MIT publications","description":"Patent documents citing scholarly work of MIT","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":143355,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:05:29Z","updated":"2019-11-29T02:59:34Z","lastEventDate":"2019-11-29T02:59:34Z"},{"id":22794,"type":"PATENT","title":"Citing LBNL publications","description":"Patent documents citing scholarly work of LBNL","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":22220,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:08:27Z","updated":"2017-08-07T05:08:27Z","lastEventDate":"2017-08-07T05:08:27Z"},{"id":22798,"type":"PATENT","title":"Citing Univ Edinburgh publications","description":"Patent documents citing scholarly work of Univ Edinburgh","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":21541,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:09:07Z","updated":"2017-08-07T05:09:07Z","lastEventDate":"2017-08-07T05:09:07Z"},{"id":22800,"type":"PATENT","title":"Citing Baylor College Med publications","description":"Patent documents citing scholarly work of Baylor College Med","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":37085,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:09:55Z","updated":"2017-08-07T05:09:55Z","lastEventDate":"2017-08-07T05:09:55Z"},{"id":22802,"type":"PATENT","title":"Citing UC System publications","description":"Patent documents citing scholarly work of UC System","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":266608,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:10:38Z","updated":"2017-08-07T05:10:38Z","lastEventDate":"2017-08-07T05:10:38Z"},{"id":22804,"type":"PATENT","title":"Citing Univ Michigan publications","description":"Patent documents citing scholarly work of Univ Michigan","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":66705,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:14:35Z","updated":"2017-08-07T05:14:35Z","lastEventDate":"2017-08-07T05:14:35Z"},{"id":22805,"type":"PATENT","title":"Citing UC San Francisco publications","description":"Patent documents citing scholarly work of UC San Francisco","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":73241,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:15:33Z","updated":"2017-08-07T05:15:33Z","lastEventDate":"2017-08-07T05:15:33Z"},{"id":22811,"type":"PATENT","title":"Citing Univ Pennsylvania publications","description":"Patent documents citing scholarly work of Univ Pennsylvania","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":65126,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:17:40Z","updated":"2017-08-07T05:17:40Z","lastEventDate":"2017-08-07T05:17:40Z"},{"id":22825,"type":"PATENT","title":"Citing Queen Mary Univ London publications","description":"Patent documents citing scholarly work of Queen Mary Univ London","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":14172,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:22:28Z","updated":"2017-08-07T05:22:28Z","lastEventDate":"2017-08-07T05:22:28Z"},{"id":22830,"type":"PATENT","title":"Citing Univ Pittsburgh publications","description":"Patent documents citing scholarly work of Univ Pittsburgh","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":39162,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:24:02Z","updated":"2017-08-07T05:24:02Z","lastEventDate":"2017-08-07T05:24:02Z"},{"id":22846,"type":"PATENT","title":"Citing Univ Chicago publications","description":"Patent documents citing scholarly work of Univ Chicago","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":39575,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:30:19Z","updated":"2017-08-07T05:30:19Z","lastEventDate":"2017-08-07T05:30:19Z"},{"id":22855,"type":"PATENT","title":"Citing University College London (UCL) publications","description":"Patent documents citing scholarly work of University College London (UCL)","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":53487,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:34:28Z","updated":"2017-08-07T05:34:28Z","lastEventDate":"2017-08-07T05:34:28Z"},{"id":22856,"type":"PATENT","title":"Citing NIH publications","description":"Patent documents citing scholarly work of NIH","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":151649,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:35:15Z","updated":"2017-08-07T05:35:15Z","lastEventDate":"2017-08-07T05:35:15Z"},{"id":22859,"type":"PATENT","title":"Citing Harvard Univ publications","description":"Patent documents citing scholarly work of Harvard Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":175224,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:37:44Z","updated":"2017-08-07T05:37:44Z","lastEventDate":"2017-08-07T05:37:44Z"},{"id":22860,"type":"PATENT","title":"Citing UC San Diego publications","description":"Patent documents citing scholarly work of UC San Diego","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":70050,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:40:14Z","updated":"2017-08-07T05:40:14Z","lastEventDate":"2017-08-07T05:40:14Z"},{"id":22864,"type":"PATENT","title":"Citing Ohio State Univ publications","description":"Patent documents citing scholarly work of Ohio State Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":31507,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:42:04Z","updated":"2017-08-07T05:42:04Z","lastEventDate":"2017-08-07T05:42:04Z"},{"id":22873,"type":"PATENT","title":"Citing Columbia Univ publications","description":"Patent documents citing scholarly work of Columbia Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":56716,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:45:21Z","updated":"2017-08-07T05:45:21Z","lastEventDate":"2017-08-07T05:45:21Z"},{"id":22877,"type":"PATENT","title":"Citing CNR publications","description":"Patent documents citing scholarly work of CNR","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":32089,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:47:06Z","updated":"2017-08-07T05:47:06Z","lastEventDate":"2017-08-07T05:47:06Z"},{"id":22878,"type":"PATENT","title":"Citing Univ London publications","description":"Patent documents citing scholarly work of Univ London","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":96093,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:47:35Z","updated":"2017-08-07T05:47:35Z","lastEventDate":"2017-08-07T05:47:35Z"},{"id":22886,"type":"PATENT","title":"Citing Univ Texas System publications","description":"Patent documents citing scholarly work of Univ Texas System","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":110344,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:51:34Z","updated":"2017-08-07T05:51:34Z","lastEventDate":"2017-08-07T05:51:34Z"},{"id":22891,"type":"PATENT","title":"Citing Indiana Univ System publications","description":"Patent documents citing scholarly work of Indiana Univ System","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":25265,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:54:11Z","updated":"2017-08-07T05:54:11Z","lastEventDate":"2017-08-07T05:54:11Z"},{"id":22893,"type":"PATENT","title":"Citing Univ Paris-Sud publications","description":"Patent documents citing scholarly work of Univ Paris-Sud","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15146,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:54:59Z","updated":"2017-08-07T05:54:59Z","lastEventDate":"2017-08-07T05:54:59Z"},{"id":22901,"type":"PATENT","title":"Citing Johns Hopkins Univ publications","description":"Patent documents citing scholarly work of Johns Hopkins Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":76487,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:56:37Z","updated":"2017-08-07T05:56:37Z","lastEventDate":"2017-08-07T05:56:37Z"},{"id":22903,"type":"PATENT","title":"Citing Kings College London publications","description":"Patent documents citing scholarly work of Kings College London","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":26647,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:58:18Z","updated":"2017-08-07T05:58:18Z","lastEventDate":"2017-08-07T05:58:18Z"},{"id":22905,"type":"PATENT","title":"Citing Peking Univ publications","description":"Patent documents citing scholarly work of Peking Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":9293,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:59:12Z","updated":"2017-08-07T05:59:12Z","lastEventDate":"2017-08-07T05:59:12Z"},{"id":22907,"type":"PATENT","title":"Citing TUM publications","description":"Patent documents citing scholarly work of TUM","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":22072,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:59:37Z","updated":"2017-08-07T05:59:37Z","lastEventDate":"2017-08-07T05:59:37Z"},{"id":22910,"type":"PATENT","title":"Citing Tufts Univ publications","description":"Patent documents citing scholarly work of Tufts Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":23852,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T06:00:26Z","updated":"2017-08-07T06:00:26Z","lastEventDate":"2017-08-07T06:00:26Z"},{"id":22911,"type":"PATENT","title":"Citing Univ Cambridge publications","description":"Patent documents citing scholarly work of Univ Cambridge","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":58870,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T06:00:47Z","updated":"2017-08-07T06:00:47Z","lastEventDate":"2017-08-07T06:00:47Z"},{"id":22914,"type":"PATENT","title":"Citing Yale Univ publications","description":"Patent documents citing scholarly work of Yale Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":53591,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T06:01:58Z","updated":"2017-08-07T06:01:58Z","lastEventDate":"2017-08-07T06:01:58Z"},{"id":23024,"type":"PATENT","title":"Citing The University of New South Wales publications","description":"Patent documents citing scholarly work of The University of New South Wales","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11568,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-15T06:21:04Z","updated":"2017-08-15T06:21:04Z","lastEventDate":"2017-08-15T06:21:04Z"},{"id":23037,"type":"PATENT","title":"Citing The University of Technology Sydney publications","description":"Patent documents citing scholarly work of The University of Technology Sydney","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1332,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-15T06:22:45Z","updated":"2017-08-15T06:22:45Z","lastEventDate":"2017-08-15T06:22:45Z"},{"id":23058,"type":"PATENT","title":"Citing QIMR Berghofer Medical Research Institute publications","description":"Patent documents citing scholarly work of QIMR Berghofer Medical Research Institute","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4027,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-15T06:24:53Z","updated":"2017-08-15T06:24:53Z","lastEventDate":"2017-08-15T06:24:53Z"},{"id":182990,"type":"PATENT","title":"2","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":49434,"tags":[],"user":{"id":320339875,"username":"tadro.abbott@csiro.au","firstName":"Tadro","lastName":"Abbott","created":"2019-06-27T07:11:33.000Z","displayName":"Tadro Abbott","preferences":"{\"usage\":\"public\"}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2020-08-10T01:50:08Z","updated":"2020-08-10T01:54:38Z","lastEventDate":"2020-08-10T01:54:38Z"},{"id":185160,"type":"PATENT","title":"CB-Patentes WO 2010 6meses","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":16726,"tags":[],"user":{"id":347486693,"username":"gemavelayos","firstName":"","lastName":"","created":"2020-03-07T17:30:23.000Z","displayName":"gemavelayos","preferences":"{\"usage\":\"public\"}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[],"created":"2020-11-06T08:56:18Z","updated":"2020-11-06T08:56:54Z","lastEventDate":"2020-11-06T08:56:54Z"},{"id":209452,"type":"PATENT","title":"Sites ACAD","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":50000,"tags":[],"user":{"id":499537341,"username":"freddriksenpaul","firstName":"","lastName":"","created":"2023-03-21T12:34:33.000Z","displayName":"freddriksenpaul","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[],"created":"2023-05-14T03:11:57Z","updated":"2023-05-14T03:12:05Z","lastEventDate":"2023-05-14T03:12:05Z"},{"id":210650,"type":"PATENT","title":"Nanogeogases 2.0","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":50000,"tags":[],"user":{"id":404479368,"username":"abnervianalens","firstName":"Abner M.","lastName":"Viana Nery","created":"2021-05-16T21:40:25.000Z","displayName":"Abner M. Viana Nery","profilePictureKey":"lens/avatar/a4885063-561e-4e8b-a53c-446b74ccfa1c","avatar":{"id":515,"key":"lens/avatar/a4885063-561e-4e8b-a53c-446b74ccfa1c"},"preferences":"{}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2023-06-26T16:53:03Z","updated":"2023-06-26T17:03:31Z","lastEventDate":"2023-06-26T17:03:31Z"}],"notes":[],"inventorships":[],"privateCollections":[],"publicCollections":[{"id":22718,"type":"PATENT","title":"Citing Vanderbilt Univ publications","description":"Patent documents citing scholarly work of Vanderbilt Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":27696,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:37:25Z","updated":"2017-08-07T04:37:25Z","lastEventDate":"2017-08-07T04:37:25Z"},{"id":22721,"type":"PATENT","title":"Citing CNRS publications","description":"Patent documents citing scholarly work of CNRS","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":129822,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:38:15Z","updated":"2017-08-07T04:38:15Z","lastEventDate":"2017-08-07T04:38:15Z"},{"id":22728,"type":"PATENT","title":"Citing UC Davis publications","description":"Patent documents citing scholarly work of UC Davis","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":34174,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:41:48Z","updated":"2017-08-07T04:41:48Z","lastEventDate":"2017-08-07T04:41:48Z"},{"id":22729,"type":"PATENT","title":"Citing UC Los Angeles publications","description":"Patent documents citing scholarly work of UC Los Angeles","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":73948,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:42:18Z","updated":"2017-08-07T04:42:18Z","lastEventDate":"2017-08-07T04:42:18Z"},{"id":22739,"type":"PATENT","title":"Citing KU Leuven publications","description":"Patent documents citing scholarly work of KU Leuven","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":30113,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:46:44Z","updated":"2017-08-07T04:46:44Z","lastEventDate":"2017-08-07T04:46:44Z"},{"id":22751,"type":"PATENT","title":"Citing UT Health Science Center publications","description":"Patent documents citing scholarly work of UT Health Science Center","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8794,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:50:40Z","updated":"2017-08-07T04:50:40Z","lastEventDate":"2017-08-07T04:50:40Z"},{"id":22757,"type":"PATENT","title":"Citing Cornell Univ publications","description":"Patent documents citing scholarly work of Cornell Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":60392,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:53:01Z","updated":"2017-08-07T04:53:01Z","lastEventDate":"2017-08-07T04:53:01Z"},{"id":22763,"type":"PATENT","title":"Citing NYU publications","description":"Patent documents citing scholarly work of NYU","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":34711,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:55:15Z","updated":"2017-08-07T04:55:15Z","lastEventDate":"2017-08-07T04:55:15Z"},{"id":22764,"type":"PATENT","title":"Citing Univ Paris Descartes publications","description":"Patent documents citing scholarly work of Univ Paris Descartes","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":10846,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:55:45Z","updated":"2017-08-07T04:55:45Z","lastEventDate":"2017-08-07T04:55:45Z"},{"id":22766,"type":"PATENT","title":"Citing McGill Univ publications","description":"Patent documents citing scholarly work of McGill Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":33777,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:56:02Z","updated":"2017-08-07T04:56:02Z","lastEventDate":"2017-08-07T04:56:02Z"},{"id":22773,"type":"PATENT","title":"Citing Univ Washington publications","description":"Patent documents citing scholarly work of Univ Washington","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":75126,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:58:47Z","updated":"2017-08-07T04:58:47Z","lastEventDate":"2017-08-07T04:58:47Z"},{"id":22779,"type":"PATENT","title":"Citing UBC publications","description":"Patent documents citing scholarly work of UBC","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":34693,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:01:43Z","updated":"2017-08-07T05:01:43Z","lastEventDate":"2017-08-07T05:01:43Z"},{"id":22786,"type":"PATENT","title":"Citing Duke Univ publications","description":"Patent documents citing scholarly work of Duke Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":52418,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:04:02Z","updated":"2017-08-07T05:04:02Z","lastEventDate":"2017-08-07T05:04:02Z"},{"id":22790,"type":"PATENT","title":"Citing MIT publications","description":"Patent documents citing scholarly work of MIT","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":143355,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:05:29Z","updated":"2019-11-29T02:59:34Z","lastEventDate":"2019-11-29T02:59:34Z"},{"id":22794,"type":"PATENT","title":"Citing LBNL publications","description":"Patent documents citing scholarly work of LBNL","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":22220,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:08:27Z","updated":"2017-08-07T05:08:27Z","lastEventDate":"2017-08-07T05:08:27Z"},{"id":22798,"type":"PATENT","title":"Citing Univ Edinburgh publications","description":"Patent documents citing scholarly work of Univ Edinburgh","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":21541,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:09:07Z","updated":"2017-08-07T05:09:07Z","lastEventDate":"2017-08-07T05:09:07Z"},{"id":22800,"type":"PATENT","title":"Citing Baylor College Med publications","description":"Patent documents citing scholarly work of Baylor College Med","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":37085,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:09:55Z","updated":"2017-08-07T05:09:55Z","lastEventDate":"2017-08-07T05:09:55Z"},{"id":22802,"type":"PATENT","title":"Citing UC System publications","description":"Patent documents citing scholarly work of UC System","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":266608,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:10:38Z","updated":"2017-08-07T05:10:38Z","lastEventDate":"2017-08-07T05:10:38Z"},{"id":22804,"type":"PATENT","title":"Citing Univ Michigan publications","description":"Patent documents citing scholarly work of Univ Michigan","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":66705,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:14:35Z","updated":"2017-08-07T05:14:35Z","lastEventDate":"2017-08-07T05:14:35Z"},{"id":22805,"type":"PATENT","title":"Citing UC San Francisco publications","description":"Patent documents citing scholarly work of UC San Francisco","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":73241,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:15:33Z","updated":"2017-08-07T05:15:33Z","lastEventDate":"2017-08-07T05:15:33Z"},{"id":22811,"type":"PATENT","title":"Citing Univ Pennsylvania publications","description":"Patent documents citing scholarly work of Univ Pennsylvania","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":65126,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:17:40Z","updated":"2017-08-07T05:17:40Z","lastEventDate":"2017-08-07T05:17:40Z"},{"id":22825,"type":"PATENT","title":"Citing Queen Mary Univ London publications","description":"Patent documents citing scholarly work of Queen Mary Univ London","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":14172,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:22:28Z","updated":"2017-08-07T05:22:28Z","lastEventDate":"2017-08-07T05:22:28Z"},{"id":22830,"type":"PATENT","title":"Citing Univ Pittsburgh publications","description":"Patent documents citing scholarly work of Univ Pittsburgh","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":39162,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:24:02Z","updated":"2017-08-07T05:24:02Z","lastEventDate":"2017-08-07T05:24:02Z"},{"id":22846,"type":"PATENT","title":"Citing Univ Chicago publications","description":"Patent documents citing scholarly work of Univ Chicago","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":39575,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:30:19Z","updated":"2017-08-07T05:30:19Z","lastEventDate":"2017-08-07T05:30:19Z"},{"id":22855,"type":"PATENT","title":"Citing University College London (UCL) publications","description":"Patent documents citing scholarly work of University College London (UCL)","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":53487,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:34:28Z","updated":"2017-08-07T05:34:28Z","lastEventDate":"2017-08-07T05:34:28Z"},{"id":22856,"type":"PATENT","title":"Citing NIH publications","description":"Patent documents citing scholarly work of NIH","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":151649,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:35:15Z","updated":"2017-08-07T05:35:15Z","lastEventDate":"2017-08-07T05:35:15Z"},{"id":22859,"type":"PATENT","title":"Citing Harvard Univ publications","description":"Patent documents citing scholarly work of Harvard Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":175224,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:37:44Z","updated":"2017-08-07T05:37:44Z","lastEventDate":"2017-08-07T05:37:44Z"},{"id":22860,"type":"PATENT","title":"Citing UC San Diego publications","description":"Patent documents citing scholarly work of UC San Diego","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":70050,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:40:14Z","updated":"2017-08-07T05:40:14Z","lastEventDate":"2017-08-07T05:40:14Z"},{"id":22864,"type":"PATENT","title":"Citing Ohio State Univ publications","description":"Patent documents citing scholarly work of Ohio State Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":31507,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:42:04Z","updated":"2017-08-07T05:42:04Z","lastEventDate":"2017-08-07T05:42:04Z"},{"id":22873,"type":"PATENT","title":"Citing Columbia Univ publications","description":"Patent documents citing scholarly work of Columbia Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":56716,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:45:21Z","updated":"2017-08-07T05:45:21Z","lastEventDate":"2017-08-07T05:45:21Z"},{"id":22877,"type":"PATENT","title":"Citing CNR publications","description":"Patent documents citing scholarly work of CNR","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":32089,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:47:06Z","updated":"2017-08-07T05:47:06Z","lastEventDate":"2017-08-07T05:47:06Z"},{"id":22878,"type":"PATENT","title":"Citing Univ London publications","description":"Patent documents citing scholarly work of Univ London","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":96093,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:47:35Z","updated":"2017-08-07T05:47:35Z","lastEventDate":"2017-08-07T05:47:35Z"},{"id":22886,"type":"PATENT","title":"Citing Univ Texas System publications","description":"Patent documents citing scholarly work of Univ Texas System","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":110344,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:51:34Z","updated":"2017-08-07T05:51:34Z","lastEventDate":"2017-08-07T05:51:34Z"},{"id":22891,"type":"PATENT","title":"Citing Indiana Univ System publications","description":"Patent documents citing scholarly work of Indiana Univ System","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":25265,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:54:11Z","updated":"2017-08-07T05:54:11Z","lastEventDate":"2017-08-07T05:54:11Z"},{"id":22893,"type":"PATENT","title":"Citing Univ Paris-Sud publications","description":"Patent documents citing scholarly work of Univ Paris-Sud","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15146,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:54:59Z","updated":"2017-08-07T05:54:59Z","lastEventDate":"2017-08-07T05:54:59Z"},{"id":22901,"type":"PATENT","title":"Citing Johns Hopkins Univ publications","description":"Patent documents citing scholarly work of Johns Hopkins Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":76487,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:56:37Z","updated":"2017-08-07T05:56:37Z","lastEventDate":"2017-08-07T05:56:37Z"},{"id":22903,"type":"PATENT","title":"Citing Kings College London publications","description":"Patent documents citing scholarly work of Kings College London","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":26647,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:58:18Z","updated":"2017-08-07T05:58:18Z","lastEventDate":"2017-08-07T05:58:18Z"},{"id":22905,"type":"PATENT","title":"Citing Peking Univ publications","description":"Patent documents citing scholarly work of Peking Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":9293,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:59:12Z","updated":"2017-08-07T05:59:12Z","lastEventDate":"2017-08-07T05:59:12Z"},{"id":22907,"type":"PATENT","title":"Citing TUM publications","description":"Patent documents citing scholarly work of TUM","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":22072,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:59:37Z","updated":"2017-08-07T05:59:37Z","lastEventDate":"2017-08-07T05:59:37Z"},{"id":22910,"type":"PATENT","title":"Citing Tufts Univ publications","description":"Patent documents citing scholarly work of Tufts Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":23852,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T06:00:26Z","updated":"2017-08-07T06:00:26Z","lastEventDate":"2017-08-07T06:00:26Z"},{"id":22911,"type":"PATENT","title":"Citing Univ Cambridge publications","description":"Patent documents citing scholarly work of Univ Cambridge","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":58870,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T06:00:47Z","updated":"2017-08-07T06:00:47Z","lastEventDate":"2017-08-07T06:00:47Z"},{"id":22914,"type":"PATENT","title":"Citing Yale Univ publications","description":"Patent documents citing scholarly work of Yale Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":53591,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T06:01:58Z","updated":"2017-08-07T06:01:58Z","lastEventDate":"2017-08-07T06:01:58Z"},{"id":23024,"type":"PATENT","title":"Citing The University of New South Wales publications","description":"Patent documents citing scholarly work of The University of New South Wales","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11568,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-15T06:21:04Z","updated":"2017-08-15T06:21:04Z","lastEventDate":"2017-08-15T06:21:04Z"},{"id":23037,"type":"PATENT","title":"Citing The University of Technology Sydney publications","description":"Patent documents citing scholarly work of The University of Technology Sydney","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1332,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-15T06:22:45Z","updated":"2017-08-15T06:22:45Z","lastEventDate":"2017-08-15T06:22:45Z"},{"id":23058,"type":"PATENT","title":"Citing QIMR Berghofer Medical Research Institute publications","description":"Patent documents citing scholarly work of QIMR Berghofer Medical Research Institute","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4027,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-15T06:24:53Z","updated":"2017-08-15T06:24:53Z","lastEventDate":"2017-08-15T06:24:53Z"},{"id":182990,"type":"PATENT","title":"2","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":49434,"tags":[],"user":{"id":320339875,"username":"tadro.abbott@csiro.au","firstName":"Tadro","lastName":"Abbott","created":"2019-06-27T07:11:33.000Z","displayName":"Tadro Abbott","preferences":"{\"usage\":\"public\"}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2020-08-10T01:50:08Z","updated":"2020-08-10T01:54:38Z","lastEventDate":"2020-08-10T01:54:38Z"},{"id":185160,"type":"PATENT","title":"CB-Patentes WO 2010 6meses","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":16726,"tags":[],"user":{"id":347486693,"username":"gemavelayos","firstName":"","lastName":"","created":"2020-03-07T17:30:23.000Z","displayName":"gemavelayos","preferences":"{\"usage\":\"public\"}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[],"created":"2020-11-06T08:56:18Z","updated":"2020-11-06T08:56:54Z","lastEventDate":"2020-11-06T08:56:54Z"},{"id":209452,"type":"PATENT","title":"Sites ACAD","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":50000,"tags":[],"user":{"id":499537341,"username":"freddriksenpaul","firstName":"","lastName":"","created":"2023-03-21T12:34:33.000Z","displayName":"freddriksenpaul","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[],"created":"2023-05-14T03:11:57Z","updated":"2023-05-14T03:12:05Z","lastEventDate":"2023-05-14T03:12:05Z"},{"id":210650,"type":"PATENT","title":"Nanogeogases 2.0","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":50000,"tags":[],"user":{"id":404479368,"username":"abnervianalens","firstName":"Abner M.","lastName":"Viana Nery","created":"2021-05-16T21:40:25.000Z","displayName":"Abner M. Viana Nery","profilePictureKey":"lens/avatar/a4885063-561e-4e8b-a53c-446b74ccfa1c","avatar":{"id":515,"key":"lens/avatar/a4885063-561e-4e8b-a53c-446b74ccfa1c"},"preferences":"{}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2023-06-26T16:53:03Z","updated":"2023-06-26T17:03:31Z","lastEventDate":"2023-06-26T17:03:31Z"}],"privateNotes":[],"landscapeCollections":[],"landscapeNotes":[]},"document":{"record_lens_id":"019-041-955-500-923","lens_id":["019-041-955-500-923","172-014-270-072-931"],"doc_key":"WO_2010138490_A1_20101202","created":"2016-01-15T15:00:46.093","docdb_id":329487554,"lens_internal":{"earliest_lens_id_created_time":"2016-01-15T15:00:46.093","last_modified":"2024-03-25T10:51:36.044","legacy_pub_key":"WO_2010_138490_A1","has_doc_lang":true,"has_biblio_lang":true,"has_all_title_lang":true,"has_all_abstract_lang":true,"has_all_claims_lang":true,"has_description_lang":true},"jurisdiction":"WO","doc_number":"2010138490","kind":"A1","date_published":"2010-12-02","year_published":2010,"ids":["WO_2010_138490_A1","019-041-955-500-923","172-014-270-072-931","WO_2010138490_A1_20101202","WO","2010138490","A1","WO2010138490A1","WO2010138490","2010138490A1"],"lang":"en","publication_type":"PATENT_APPLICATION","application_reference":{"jurisdiction":"US","doc_number":"2010036038","kind":"W","date":"2010-05-25"},"priority_claim":[{"jurisdiction":"US","doc_number":"21714509","kind":"P","date":"2009-05-26"}],"priority_claim.source":"DOCDB","earliest_priority_claim_date":"2009-05-26","title":{"en":[{"text":"BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE","lang":"en","source":"DOCDB","data_format":"DOCDBA"}],"fr":[{"text":"BENZOXAZÈPINES COMME INHIBITEURS DE MTOR ET MÉTHODES D'UTILISATION ET DE FABRICATION","lang":"fr","source":"DOCDB","data_format":"DOCDBA"}]},"title_lang":["en","fr"],"has_title":true,"applicant":[{"name":"EXELIXIS INC","residence":"US","sequence":1,"app_type":"applicant"},{"name":"AAY NAING","residence":"US","sequence":2,"app_type":"applicant"},{"name":"BLAZEY CHARLES M","residence":"US","sequence":3,"app_type":"applicant"},{"name":"BOWLES OWEN JOSEPH","residence":"US","sequence":4,"app_type":"applicant"},{"name":"BUSSENIUS JOERG","residence":"US","sequence":5,"app_type":"applicant"},{"name":"CURTIS JEFFRY KIMO","residence":"US","sequence":6,"app_type":"applicant"},{"name":"DEFINA STEVEN CHARLES","residence":"US","sequence":7,"app_type":"applicant"},{"name":"DUBENKO LARISA","residence":"US","sequence":8,"app_type":"applicant"},{"name":"HARRIS JASON R","residence":"US","sequence":9,"app_type":"applicant"},{"name":"JACKSON-UGUETO EILEEN E","residence":"US","sequence":10,"app_type":"applicant"},{"name":"KIM ANGIE INYOUNG","residence":"US","sequence":11,"app_type":"applicant"},{"name":"MANALO JEAN-CLAIRE LIMUN","residence":"US","sequence":12,"app_type":"applicant"},{"name":"PACK MICHAEL","residence":"US","sequence":13,"app_type":"applicant"},{"name":"PETO CSABA J","residence":"US","sequence":14,"app_type":"applicant"},{"name":"RICE KENNETH D","residence":"US","sequence":15,"app_type":"applicant"},{"name":"TSANG TSZE H","residence":"US","sequence":16,"app_type":"applicant"},{"name":"WANG LONGCHENG","residence":"US","sequence":17,"app_type":"applicant"}],"applicant_count":17,"has_applicant":true,"inventor":[{"name":"AAY NAING","residence":"US","sequence":1},{"name":"BLAZEY CHARLES M","residence":"US","sequence":2},{"name":"BOWLES OWEN JOSEPH","residence":"US","sequence":3},{"name":"BUSSENIUS JOERG","residence":"US","sequence":4},{"name":"CURTIS JEFFRY KIMO","residence":"US","sequence":5},{"name":"DEFINA STEVEN CHARLES","residence":"US","sequence":6},{"name":"DUBENKO LARISA","residence":"US","sequence":7},{"name":"HARRIS JASON R","residence":"US","sequence":8},{"name":"JACKSON-UGUETO EILEEN E","residence":"US","sequence":9},{"name":"KIM ANGIE INYOUNG","residence":"US","sequence":10},{"name":"MANALO JEAN-CLAIRE LIMUN","residence":"US","sequence":11},{"name":"PACK MICHAEL","residence":"US","sequence":12},{"name":"PETO CSABA J","residence":"US","sequence":13},{"name":"RICE KENNETH D","residence":"US","sequence":14},{"name":"TSANG TSZE H","residence":"US","sequence":15},{"name":"WANG LONGCHENG","residence":"US","sequence":16}],"inventor_count":16,"has_inventor":true,"agent":[{"name":"O'BRIEN, Jonathan, P. et al.","address":"Honigman Miller Schwartz and Cohn LLP, 350 East Michigan Avenue, Suite 300, Kalamazoo, Michigan 49007-3800, 49007-3800","country":"US","sequence":1}],"agent_count":1,"has_agent":true,"owner":[],"owner_count":0,"owner_all":[],"owner_all_count":0,"has_owner":false,"has_examiner":false,"class_ipcr":[{"symbol":"C07D413/04","version_indicator":"2006-01-01","class_symbol_position":"F","class_value":"I","action_date":"2010-12-02","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":1},{"symbol":"A61K31/553","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2010-12-02","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":2},{"symbol":"A61P35/00","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2010-12-02","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":3},{"symbol":"C07D413/14","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2010-12-02","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":4},{"symbol":"C07D417/14","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2010-12-02","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":5},{"symbol":"C07D471/08","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2010-12-02","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":6},{"symbol":"C07D487/08","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2010-12-02","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":7},{"symbol":"C07D519/00","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2010-12-02","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":8}],"class_ipcr.first_symbol":"C07D413/04","class_ipcr.later_symbol":["A61K31/553","A61P35/00","C07D413/14","C07D417/14","C07D471/08","C07D487/08","C07D519/00"],"class_ipcr.inv_symbol":["C07D413/04","A61K31/553","A61P35/00","C07D413/14","C07D417/14","C07D471/08","C07D487/08","C07D519/00"],"class_ipcr.add_symbol":[],"class_ipcr.source":"DOCDB","class_cpc":[{"symbol":"A61P35/00","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-27","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":1},{"symbol":"C07D413/04","version_indicator":"2013-01-01","class_symbol_position":"F","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":2},{"symbol":"C07D413/14","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":3},{"symbol":"C07D417/14","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":4},{"symbol":"C07D451/02","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":5},{"symbol":"C07D451/04","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":6},{"symbol":"C07D451/06","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":7},{"symbol":"C07D453/06","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":8},{"symbol":"C07D487/08","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":9}],"class_cpc_cset":[],"class_cpc.first_symbol":"C07D413/04","class_cpc.later_symbol":["A61P35/00","C07D413/14","C07D417/14","C07D451/02","C07D451/04","C07D451/06","C07D453/06","C07D487/08"],"class_cpc.inv_symbol":["A61P35/00","C07D413/04","C07D413/14","C07D417/14","C07D451/02","C07D451/04","C07D451/06","C07D453/06","C07D487/08"],"class_cpc.add_symbol":[],"class_cpc.source":"DOCDB","class_national":[],"class_national.later_symbol":[],"reference_cited":[{"npl":{"num":1,"text":"DANCEY: \"Inhibitors of the mammalian target of rapamycin\", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 14, no. 3, 1 March 2005 (2005-03-01), pages 313 - 328, XP002596251","npl_type":"s","xp_number":"002596251","external_id":["10.1517/13543784.14.3.313","15833062"],"record_lens_id":"027-812-245-649-742","lens_id":["148-037-747-782-407","027-812-245-649-742","160-330-032-569-095"],"sequence":1,"category":["A"],"us_category":[],"cited_phase":"ISR","cited_date":"2010-08-18","rel_claims":[],"srep_office":"EP"}},{"patent":{"num":1,"document_id":{"jurisdiction":"WO","doc_number":"2008144483","kind":"A2","date":"2008-11-27","name":"ARMGO PHARMA INC [US], et al"},"lens_id":"191-682-471-579-74X","srep_office":"EP","category":["A"],"us_category":[],"cited_phase":"ISR","cited_date":"2010-08-18","rel_claims":[],"sequence":2}},{"patent":{"num":2,"document_id":{"jurisdiction":"WO","doc_number":"2004014851","kind":"A2","date":"2004-02-19","name":"MERCK & CO INC [US], et al"},"lens_id":"127-092-014-749-343","srep_office":"EP","category":["A"],"us_category":[],"cited_phase":"ISR","cited_date":"2010-08-18","rel_claims":[],"sequence":3}},{"npl":{"num":2,"text":"DIAZ-GAVILAN M ET AL: \"Synthesis of tetrahydrobenzoxazepine acetals with electron-withdrawing groups on the nitrogen atom. Novel scaffolds endowed with anticancer activity against breast cancer cells\", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL LNKD- DOI:10.1016/J.TET.2004.09.072, vol. 60, no. 50, 6 December 2004 (2004-12-06), pages 11547 - 11557, XP004628617, ISSN: 0040-4020","npl_type":"s","xp_number":"004628617","external_id":["10.1016/j.tet.2004.09.072"],"record_lens_id":"059-364-375-330-195","lens_id":["123-411-176-009-751","059-364-375-330-195"],"sequence":4,"category":["A"],"us_category":[],"cited_phase":"ISR","cited_date":"2010-08-18","rel_claims":[],"srep_office":"EP"}},{"npl":{"num":1,"text":"BJOMSTI; HOUGHTON, REV CANCER, vol. 4, no. 5, 2004, pages 335 - 48","npl_type":"s","external_id":[],"lens_id":[],"sequence":1,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":2,"text":"HOUGHTON; HUANG, MICROBIOL IMMUNOL, vol. 279, 2004, pages 339 - 59","npl_type":"s","external_id":["14560967","10.1007/978-3-642-18930-2_20"],"record_lens_id":"004-817-396-897-928","lens_id":["189-125-838-282-974","035-024-353-010-391","004-817-396-897-928"],"sequence":2,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":3,"text":"INOKI, CORRADETTI ET AL., NAT GENET, vol. 37, no. 1, 2005, pages 19 - 24","npl_type":"s","external_id":["10.1038/ng1494","15624019"],"record_lens_id":"094-752-256-212-560","lens_id":["192-805-790-283-106","094-752-256-212-560","136-887-941-696-815"],"sequence":3,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":4,"text":"NAGATA, LAN ET AL., CANCER CELL, vol. 6, no. 2, 2004, pages 117 - 27","npl_type":"s","external_id":["15324695","10.1016/j.ccr.2004.06.022"],"record_lens_id":"076-059-062-130-42X","lens_id":["164-494-500-599-209","076-059-062-130-42X","192-153-996-991-561"],"sequence":4,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":5,"text":"PANDOLFI, N ENGL J MED, vol. 351, no. 22, 2004, pages 2337 - 8","npl_type":"s","external_id":["10.1056/nejmcibr043143","15564551"],"record_lens_id":"098-096-993-138-885","lens_id":["182-816-966-020-109","098-096-993-138-885","170-592-632-218-814"],"sequence":5,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":6,"text":"NAHTA, YU ET AL., NAT CLIN PRACT ONCOL, vol. 3, no. 5, 2006, pages 269 - 280","npl_type":"s","external_id":["16683005","10.1038/ncponc0509"],"record_lens_id":"036-294-839-691-525","lens_id":["116-496-134-885-51X","036-294-839-691-525","052-849-117-226-679"],"sequence":6,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":7,"text":"DAL COL, ZANCAI ET AL., BLOOD, vol. 111, no. 10, 2008, pages 5142 - 51","npl_type":"s","external_id":["10.1182/blood-2007-07-103481","18339899"],"record_lens_id":"048-393-608-735-876","lens_id":["078-334-362-797-281","128-259-485-861-575","048-393-608-735-876"],"sequence":7,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":8,"text":"THOMAS, TRAN ET AL., NAT MED, vol. 12, no. 1, 2006, pages 122 - 7","npl_type":"s","external_id":[],"lens_id":[],"sequence":8,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":9,"text":"ATKINS, HIDALGO ET AL., J CLIN ONCOL, vol. 22, no. 5, 2004, pages 909 - 18","npl_type":"s","external_id":["10.1200/jco.2004.08.185","14990647"],"record_lens_id":"027-114-731-035-115","lens_id":["056-716-303-179-497","027-114-731-035-115","193-666-174-217-737"],"sequence":9,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":10,"text":"MOTZER, HUDES ET AL., J CLIN ONCOL, vol. 25, no. 25, 2007, pages 3958 - 64","npl_type":"s","external_id":["17761980","10.1200/jco.2006.10.5916"],"record_lens_id":"093-241-159-702-911","lens_id":["102-323-741-727-675","093-241-159-702-911","106-742-846-083-679"],"sequence":10,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":11,"text":"SUJOBERT, BARDET ET AL., BLOOD, vol. 106, no. 3, 2005, pages 1063 - 6","npl_type":"s","external_id":["15840695","10.1182/blood-2004-08-3225"],"record_lens_id":"058-987-292-314-944","lens_id":["140-916-524-998-120","058-987-292-314-944","197-559-188-370-945"],"sequence":11,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":12,"text":"BILLOTTET, GRANDAGE ET AL., ONCOGENE, vol. 25, no. 50, 2006, pages 6648 - 6659","npl_type":"s","external_id":["16702948","10.1038/sj.onc.1209670"],"record_lens_id":"073-298-018-636-588","lens_id":["158-588-262-106-113","073-298-018-636-588","176-626-807-095-897"],"sequence":12,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":13,"text":"TAMBURINI, ELIE ET AL., BLOOD, vol. 110, no. 3, 2007, pages 1025 - 8","npl_type":"s","external_id":["10.1182/blood-2006-12-061283","17426258"],"record_lens_id":"126-344-230-332-560","lens_id":["199-530-940-827-960","126-344-230-332-560","197-090-131-263-297"],"sequence":13,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":14,"text":"SKORSKI, BCLLACOSA ET AL., EMBO J, vol. 16, no. 20, 1997, pages 6151 - 61","npl_type":"s","external_id":["10.1093/emboj/16.20.6151","pmc1326299","9321394"],"record_lens_id":"075-079-861-188-048","lens_id":["142-666-408-158-443","075-079-861-188-048","095-152-576-735-878"],"sequence":14,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":15,"text":"BAI, OUYANG ET AL., BLOOD, vol. 96, no. 13, 2000, pages 4319 - 27","npl_type":"s","external_id":["10.1182/blood.v96.13.4319","11110708"],"record_lens_id":"001-018-294-469-172","lens_id":["152-431-616-163-50X","001-018-294-469-172","120-189-940-700-895"],"sequence":15,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":16,"text":"HICKEY; COTTER, BIOL CHEM, vol. 281, no. 5, 2006, pages 2441 - 50","npl_type":"s","external_id":["10.1074/jbc.m511173200","16291747"],"record_lens_id":"051-370-676-627-646","lens_id":["110-462-497-284-891","051-370-676-627-646","192-775-171-985-50X"],"sequence":16,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":17,"text":"UDDIN, HUSSAIN ET AL., BLOOD, vol. 108, no. 13, 2006, pages 4178 - 86","npl_type":"s","external_id":["10.1182/blood-2006-04-016907","16946303"],"record_lens_id":"014-480-876-382-087","lens_id":["032-957-658-055-043","014-480-876-382-087","125-865-771-642-585"],"sequence":17,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":18,"text":"HERNANDO, CHARYTONOWICZ ET AL., NAT MED, vol. 13, no. 6, 2007, pages 748 - 53","npl_type":"s","external_id":["17496901","10.1038/nm1560"],"record_lens_id":"008-996-147-124-790","lens_id":["076-885-683-951-399","008-996-147-124-790","192-133-475-594-132"],"sequence":18,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":19,"text":"WAN; HELMAN, ONCOLOGIST, vol. 12, no. 8, 2007, pages 1007 - 18","npl_type":"s","external_id":["17766661","10.1634/theoncologist.12-8-1007"],"record_lens_id":"001-967-784-177-441","lens_id":["173-497-982-046-171","001-967-784-177-441","028-512-396-668-280"],"sequence":19,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":20,"text":"CAO, YU ET AL., CANCER RES, vol. 68, no. 19, 2008, pages 8039 - 8048","npl_type":"s","external_id":["pmc2671680","10.1158/0008-5472.can-08-1712","18829562"],"record_lens_id":"038-629-167-809-678","lens_id":["150-779-205-504-423","115-084-825-476-46X","038-629-167-809-678"],"sequence":20,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":21,"text":"WAN, SHEN ET AL., NEOPLASIA, vol. 8, no. 5, 2006, pages 394 - 401","npl_type":"s","external_id":["pmc1592447","10.1593/neo.05820","16790088"],"record_lens_id":"004-922-934-054-181","lens_id":["119-065-259-816-950","004-922-934-054-181","035-963-922-010-064"],"sequence":21,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":22,"text":"SHAYESTEH, LU ET AL., NAT GENET, vol. 21, no. 1, 1999, pages 99 - 102","npl_type":"s","external_id":["9916799","10.1038/5042"],"record_lens_id":"082-600-475-212-300","lens_id":["129-077-927-492-041","082-600-475-212-300","115-356-065-397-22X"],"sequence":22,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":23,"text":"LEE, CHOI ET AL., GYNECOL ONCOL, vol. 97, no. 1, 2005, pages 26 - 34","npl_type":"s","external_id":[],"lens_id":[],"sequence":23,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":24,"text":"OBATA, MORLAND ET AL., CANCER RES, vol. 58, no. 10, 1998, pages 2095 - 7","npl_type":"s","external_id":["9605750"],"record_lens_id":"047-172-191-886-752","lens_id":["129-275-391-641-471","047-172-191-886-752"],"sequence":24,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":25,"text":"LU, WU ET AL., CLIN CANCER RES, vol. 14, no. 9, 2008, pages 2543 - 50","npl_type":"s","external_id":["18451215","10.1158/1078-0432.ccr-07-0321"],"record_lens_id":"013-268-700-041-348","lens_id":["190-215-042-461-066","030-336-672-477-926","013-268-700-041-348"],"sequence":25,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":26,"text":"TANG, HE ET AL., LUNG CANCER, vol. 51, no. 2, 2006, pages 181 - 91","npl_type":"s","external_id":["10.1016/j.lungcan.2005.10.003","16324768"],"record_lens_id":"026-735-185-637-164","lens_id":["197-462-858-896-479","026-735-185-637-164","154-752-271-091-650"],"sequence":26,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":27,"text":"MARSIT, ZHENG ET AL., HUM PATHOL, vol. 36, no. 7, 2005, pages 768 - 76","npl_type":"s","external_id":["10.1016/j.humpath.2005.05.006","16084946"],"record_lens_id":"021-629-394-896-751","lens_id":["118-109-194-346-083","021-629-394-896-751","069-597-632-388-92X"],"sequence":27,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":28,"text":"MASSION, TAFLAN ET AL., AM JRESPIR CRIT CARE MED, vol. 170, no. 10, 2004, pages 1088 - 94","npl_type":"s","external_id":["10.1164/rccm.200404-487oc","15317667"],"record_lens_id":"061-184-352-350-322","lens_id":["118-580-994-415-82X","061-184-352-350-322","096-526-577-506-364"],"sequence":28,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":29,"text":"KOKUBO, GEMMA ET AL., BR J CANCER, vol. 92, no. 9, 2005, pages 1711 - 9","npl_type":"s","external_id":["10.1038/sj.bjc.6602559","pmc2362053","15870831"],"record_lens_id":"018-290-179-464-499","lens_id":["031-390-731-906-828","018-290-179-464-499","042-519-870-528-381"],"sequence":29,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":30,"text":"PAO, WANG ET AL., PUB LIBRARY OF SCIENCE MED, vol. 2, no. 1, 2005, pages E17","npl_type":"s","external_id":[],"lens_id":[],"sequence":30,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":31,"text":"VELHO, OLIVEIRA ET AL., EUR J CANCER, vol. 41, no. 11, 2005, pages 1649 - 54","npl_type":"s","external_id":["10.1016/j.ejca.2005.04.022","15994075"],"record_lens_id":"079-559-800-108-794","lens_id":["150-695-221-431-174","079-559-800-108-794","103-564-870-469-549"],"sequence":31,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":32,"text":"FOUKAS, CLARET ET AL., NATURE, vol. 441, no. 7091, 2006, pages 366 - 370","npl_type":"s","external_id":["16625210","10.1038/nature04694"],"record_lens_id":"041-148-083-291-884","lens_id":["168-198-614-624-280","041-148-083-291-884","082-651-574-072-171"],"sequence":32,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":33,"text":"GOEL, ARNOLD ET AL., CANCER RES, vol. 64, no. 9, 2004, pages 3014 - 21","npl_type":"s","external_id":["15126336","10.1158/0008-5472.can-2401-2"],"record_lens_id":"092-286-730-436-855","lens_id":["181-255-790-411-953","092-286-730-436-855","116-045-977-385-035"],"sequence":33,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":34,"text":"NASSIF, LOBO ET AL., ONCOGENE, vol. 23, no. 2, 2004, pages 617 - 28","npl_type":"s","external_id":["14724591","10.1038/sj.onc.1207059"],"record_lens_id":"028-570-716-862-994","lens_id":["158-659-372-609-307","028-570-716-862-994","074-981-124-890-929"],"sequence":34,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":35,"text":"BOS, CANCER RES, vol. 49, no. 17, 1989, pages 4682 - 9","npl_type":"s","external_id":["2547513","0002547513"],"record_lens_id":"009-085-080-176-56X","lens_id":["070-374-182-202-936","009-085-080-176-56X"],"sequence":35,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":36,"text":"FEARON, ANN N YACAD SCI, vol. 768, 1995, pages 101 - 10","npl_type":"s","external_id":["10.1111/j.1749-6632.1995.tb12114.x","8526339"],"record_lens_id":"141-168-394-080-746","lens_id":["183-220-587-564-690","141-168-394-080-746","170-223-314-670-713"],"sequence":36,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":37,"text":"BYUN, CHO ET AL., INT J CANCER, vol. 104, no. 3, 2003, pages 318 - 27","npl_type":"s","external_id":["10.1002/ijc.10962","12569555"],"record_lens_id":"100-966-751-832-168","lens_id":["126-736-733-163-255","100-966-751-832-168","144-212-212-126-454"],"sequence":37,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":38,"text":"LEE, SOUNG ET AL., ONCOGENE, vol. 24, no. 8, 2005, pages 1477 - 80","npl_type":"s","external_id":["15608678","10.1038/sj.onc.1208304"],"record_lens_id":"046-537-777-615-696","lens_id":["183-200-560-601-908","046-537-777-615-696","050-001-207-770-167"],"sequence":38,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":39,"text":"HU, HUANG ET AL., CANCER, vol. 97, no. 8, 2003, pages 1929 - 40","npl_type":"s","external_id":["12673720","10.1002/cncr.11266"],"record_lens_id":"110-428-737-717-010","lens_id":["177-256-418-354-34X","110-428-737-717-010","162-396-429-635-286"],"sequence":39,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":40,"text":"WAN, JIANG ET AL., CANCER RES CLIN ONCOL, vol. 129, no. 2, 2003, pages 100 - 6","npl_type":"s","external_id":["10.1007/s00432-002-0410-x","12669234"],"record_lens_id":"032-618-940-034-282","lens_id":["056-688-442-741-720","032-618-940-034-282","118-913-945-825-518"],"sequence":40,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":41,"text":"GULDBERG, THOR STRATEN ET AL., CANCER RES, vol. 57, no. 17, 1997, pages 3660 - 3","npl_type":"s","external_id":["9288767"],"record_lens_id":"067-349-350-491-296","lens_id":["194-874-288-847-246","067-349-350-491-296"],"sequence":41,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":42,"text":"TSAO, ZHANG ET AL., CANCER RES, vol. 60, no. 7, 2000, pages 1800 - 4","npl_type":"s","external_id":["10766161"],"record_lens_id":"000-271-284-251-367","lens_id":["089-962-786-762-505","000-271-284-251-367"],"sequence":42,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":43,"text":"WHITEMAN, ZHOU ET AL., INT J CANCER, vol. 99, no. 1, 2002, pages 63 - 7","npl_type":"s","external_id":["11948493","10.1002/ijc.10294"],"record_lens_id":"023-470-168-748-33X","lens_id":["180-744-342-238-211","023-470-168-748-33X","111-343-881-921-212"],"sequence":43,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":44,"text":"GOEL, LAZAR ET AL., J INVEST DERINATOL, vol. 126, no. 1, 2006, pages 154 - 60","npl_type":"s","external_id":["10.1038/sj.jid.5700026","16417231"],"record_lens_id":"045-971-461-446-975","lens_id":["072-348-869-140-296","045-971-461-446-975","135-738-811-750-400"],"sequence":44,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":45,"text":"ASANO, YAO ET AL., ONCOGENE, vol. 23, no. 53, 2004, pages 8571 - 80","npl_type":"s","external_id":["15467756","10.1038/sj.onc.1207902"],"record_lens_id":"046-254-354-085-419","lens_id":["152-538-565-492-732","046-254-354-085-419","077-697-785-219-287"],"sequence":45,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":46,"text":"CAIRNS, OKAMI ET AL., CANCER RES, vol. 57, no. 22, 1997, pages 4997 - 5000","npl_type":"s","external_id":["9371490"],"record_lens_id":"178-340-551-087-939","lens_id":["192-409-820-496-838","178-340-551-087-939"],"sequence":46,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":47,"text":"GRAY, STEWART ET AL., BR J CANCER, vol. 78, no. 10, 1998, pages 1296 - 300","npl_type":"s","external_id":["pmc2063186","10.1038/bjc.1998.674","9823969"],"record_lens_id":"004-726-812-939-557","lens_id":["006-438-093-066-708","004-726-812-939-557","028-409-244-189-701"],"sequence":47,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":48,"text":"WANG, PARSONS ET AL., CLIN CANCER RES, vol. 4, no. 3, 1998, pages 811 - 5","npl_type":"s","external_id":["9533551"],"record_lens_id":"154-706-032-084-413","lens_id":["195-058-351-188-29X","154-706-032-084-413"],"sequence":48,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":49,"text":"WHANG, WU ET AL., PROC NATL ACAD SCI US A, vol. 95, no. 9, 1998, pages 5246 - 50","npl_type":"s","external_id":["pmc20246","10.1073/pnas.95.9.5246","9560261"],"record_lens_id":"043-678-312-389-887","lens_id":["062-306-403-075-252","043-678-312-389-887","125-989-486-775-084"],"sequence":49,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":50,"text":"MAJUMDER AND SELLERS, ONCOGENE, vol. 24, no. 50, 2005, pages 7465 - 74","npl_type":"s","external_id":["10.1038/sj.onc.1209096","16288293"],"record_lens_id":"071-624-410-336-422","lens_id":["174-381-148-440-240","071-624-410-336-422","090-196-692-394-233"],"sequence":50,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":51,"text":"WANG, GARCIA ET AL., PROC NATL ACAD SCI US A, vol. 103, no. 5, 2006, pages 1480 - 5","npl_type":"s","external_id":["10.1073/pnas.0510652103","16432235","pmc1345717"],"record_lens_id":"005-936-685-363-816","lens_id":["136-084-192-399-602","005-936-685-363-816","077-214-810-493-888"],"sequence":51,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":52,"text":"LU, REN ET AL., INT J ONCOL, vol. 28, no. 1, 2006, pages 245 - 51","npl_type":"s","external_id":[],"lens_id":[],"sequence":52,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":53,"text":"MULHOLLAND, DEDHAR ET AL., ONCOGENE, vol. 25, no. 3, 2006, pages 329 - 37","npl_type":"s","external_id":["10.1038/sj.onc.1209020","16421604"],"record_lens_id":"022-267-874-759-810","lens_id":["149-755-413-434-27X","022-267-874-759-810","027-294-423-782-865"],"sequence":53,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":54,"text":"XIN, TEITELL ET AL., PROC NATL ACAD SCI USA, vol. 03, no. 20, 2006, pages 7789 - 94","npl_type":"s","external_id":[],"lens_id":[],"sequence":54,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":55,"text":"MIKHAILOVA, WANG ET AL., ADV EXP MED BIOL, vol. 617, 2008, pages 397 - 405","npl_type":"s","external_id":["10.1007/978-0-387-69080-3_38","18497063"],"record_lens_id":"055-883-132-111-560","lens_id":["145-805-106-981-588","124-797-857-736-058","055-883-132-111-560"],"sequence":55,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":56,"text":"WANG, MIKHAILOVA ET AL., ONCOGENE, vol. 27, no. 56, 2008, pages 7106 - 7117","npl_type":"s","external_id":["18776922","pmc2694040","10.1038/onc.2008.318"],"record_lens_id":"048-026-953-939-12X","lens_id":["117-288-593-894-255","179-519-965-165-040","048-026-953-939-12X"],"sequence":56,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":57,"text":"GARCIA-ROSTAN, COSTA ET AL., CANCER RES, vol. 65, no. 22, 2005, pages 10199 - 207","npl_type":"s","external_id":["10.1158/0008-5472.can-04-4259","16288007"],"record_lens_id":"030-958-415-278-738","lens_id":["102-996-068-853-255","030-958-415-278-738","133-674-488-742-810"],"sequence":57,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":58,"text":"WU, MAMBO ET AL., J CLIN ENDOCRINOL METAB, vol. 90, no. 8, 2005, pages 4688 - 93","npl_type":"s","external_id":["15928251","10.1210/jc.2004-2281"],"record_lens_id":"028-000-528-837-594","lens_id":["198-788-623-405-547","028-000-528-837-594","049-326-274-113-757"],"sequence":58,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":59,"text":"BISSLER, MCCORMACK ET AL., N ENGL J MED, vol. 358, no. 2, 2008, pages 140 - 151","npl_type":"s","external_id":["pmc3398441","10.1056/nejmoa063564","18184959"],"record_lens_id":"067-786-329-512-30X","lens_id":["148-378-897-284-767","080-457-420-119-940","067-786-329-512-30X"],"sequence":59,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":60,"text":"RANDA M. S. AMIN, PATHOLOGY INTERNATIONAL, vol. 58, no. 1, 2008, pages 38 - 44","npl_type":"s","external_id":["18067639","10.1111/j.1440-1827.2007.02186.x"],"record_lens_id":"082-372-992-554-438","lens_id":["166-669-294-803-233","082-372-992-554-438","143-962-585-633-367"],"sequence":60,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":61,"text":"GUPTA, MCKENNA ET AL., CLIN CANCER RES, vol. 8, no. 3, 2002, pages 885 - 892","npl_type":"s","external_id":["11895923"],"record_lens_id":"134-165-239-651-433","lens_id":["156-719-902-284-095","134-165-239-651-433"],"sequence":61,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":62,"text":"FERNER EURJ HUM GENET, vol. 15, no. 2, 2006, pages 131 - 138","npl_type":"s","external_id":["16957683","10.1038/sj.ejhg.5201676"],"record_lens_id":"026-954-003-435-263","lens_id":["026-954-003-435-263","069-348-868-287-503","168-198-404-660-38X"],"sequence":62,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":63,"text":"SABATINI NAT REV CANCER, vol. 6, no. 9, 2006, pages 729 - 734","npl_type":"s","external_id":["16915295","10.1038/nrc1974"],"record_lens_id":"045-995-811-953-43X","lens_id":["085-456-340-822-561","045-995-811-953-43X","196-265-422-943-36X"],"sequence":63,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":64,"text":"JOHNSON ET AL., CURRENT BIOLOGY, vol. 18, no. 1, 2008, pages 56 - 62","npl_type":"s","external_id":[],"lens_id":[],"sequence":64,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":65,"text":"S. M. BERGE ET AL.: \"Pharmaceutical Salts\", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104","npl_type":"s","xp_number":"002675560","external_id":[],"lens_id":[],"sequence":65,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":66,"text":"J. LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 42, 1999, pages 1289 - 1300","npl_type":"s","external_id":[],"lens_id":[],"sequence":66,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":67,"text":"TETRAHEDRON LETT., vol. 27, 1986, pages 4549 - 4552","npl_type":"s","external_id":["10.1016/s0040-4039(00)85000-5"],"record_lens_id":"010-814-927-988-217","lens_id":["145-745-973-823-738","010-814-927-988-217"],"sequence":67,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":68,"text":"J. AM. CHEM. SOC., vol. 66, 2001, pages 2181 - 2182","npl_type":"s","external_id":[],"lens_id":[],"sequence":68,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}},{"npl":{"num":69,"text":"HUAXUE SHIJI, vol. 24, no. 3, 2002, pages 165 - 166","npl_type":"s","external_id":[],"lens_id":[],"sequence":69,"category":[],"us_category":[],"cited_phase":"APP","cited_date":"2011-11-17","rel_claims":[]}}],"reference_cited.source":"DOCDB","reference_cited.patent_count":2,"cites_patent":true,"reference_cited.npl_count":71,"reference_cited.npl_resolved_count":60,"cites_npl":true,"cites_resolved_npl":true,"cited_by":{"patent_count":15,"patent":[{"lens_id":"101-672-239-842-052","document_id":{"jurisdiction":"WO","doc_number":"2012068096","kind":"A3"}},{"lens_id":"066-835-453-502-813","document_id":{"jurisdiction":"WO","doc_number":"2012068106","kind":"A3"}},{"lens_id":"100-303-405-726-429","document_id":{"jurisdiction":"US","doc_number":"10696655","kind":"B2"}},{"lens_id":"117-335-795-305-163","document_id":{"jurisdiction":"WO","doc_number":"2012071509","kind":"A3"}},{"lens_id":"079-007-624-763-670","document_id":{"jurisdiction":"JP","doc_number":"2019516757","kind":"A"}},{"lens_id":"129-645-826-928-945","document_id":{"jurisdiction":"US","doc_number":"11795168","kind":"B2"}},{"lens_id":"097-357-689-693-792","document_id":{"jurisdiction":"WO","doc_number":"2017205536","kind":"A3"}},{"lens_id":"047-100-123-293-629","document_id":{"jurisdiction":"US","doc_number":"11168070","kind":"B2"}},{"lens_id":"148-407-879-715-041","document_id":{"jurisdiction":"US","doc_number":"11292791","kind":"B2"}},{"lens_id":"157-587-386-912-327","document_id":{"jurisdiction":"US","doc_number":"11787803","kind":"B2"}},{"lens_id":"168-951-552-337-856","document_id":{"jurisdiction":"CN","doc_number":"109476641","kind":"A"}},{"lens_id":"127-906-231-795-274","document_id":{"jurisdiction":"US","doc_number":"11801243","kind":"B2"}},{"lens_id":"008-415-551-969-420","document_id":{"jurisdiction":"WO","doc_number":"2014054053","kind":"A1"}},{"lens_id":"182-417-298-734-57X","document_id":{"jurisdiction":"US","doc_number":"10870648","kind":"B2"}},{"lens_id":"015-571-220-141-141","document_id":{"jurisdiction":"US","doc_number":"11254674","kind":"B2"}}]},"cited_by_patent":true,"family":{"simple":{"size":1,"id":156173503,"member":[{"lens_id":"019-041-955-500-923","document_id":{"jurisdiction":"WO","doc_number":"2010138490","kind":"A1","date":"2010-12-02"}}]},"extended":{"size":1,"id":156173503,"member":[{"lens_id":"019-041-955-500-923","document_id":{"jurisdiction":"WO","doc_number":"2010138490","kind":"A1","date":"2010-12-02"}}]}},"has_sequence":false,"legal_status":{"ipr_type":"patent for invention","granted":false,"earliest_filing_date":"2010-05-25","has_disclaimer":false,"patent_status":"PENDING","publication_count":1,"has_spc":false,"has_grant_event":false,"has_entry_into_national_phase":false},"abstract":{"en":[{"text":"The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula wherein the combination of R 1 and R 2 are as defined herein, and pharmaceutically acceptable salts thereof.","lang":"en","source":"WIPO_FULLTEXT","data_format":"ORIGINAL"}],"fr":[{"text":"L'invention concerne des inhibiteurs de mTOR et de sels ou des solvates pharmaceutiquement acceptables de ces inhibiteurs, ainsi que leurs méthodes d'utilisation. De façon générale, ces inhibiteurs sont représentés par la formule structurelle suivante, dans laquelle R1 et R2 sont comme définis dans le descriptif.","lang":"fr","source":"WIPO_FULLTEXT","data_format":"ORIGINAL"}]},"abstract_lang":["en","fr"],"has_abstract":true,"claim":{"en":[{"text":"What is claimed is: 1. A compound of structural formula when the combination of R 1 and R 2 are as defined in one of the following compounds: 4-{4-[(4-methylpipeπdin-l-yl)carboπyl]-2,3,4,5-tetrahydro-l,4-beπzoxazepin-7-yl}-Λ^-[(3Λ)-pyrrolidm-3- yl]benzamide Λ r -methyl-6-{4-[(4-methylpipeπdin-l-yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepm-7-yl}pyπdme-3- carboxamide 4-[(4-methylpiperidm-l-yl)carbonyl]-7-(2 -methyl- 1, 3 -thiazol-5-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepme 4- { [4-(2,3 -dimethylphenyl)piperazm- 1 -yl] carbonyl} -7-(2 -methyl- 177-benzimidazol-6-yl)-2,3 ,4,5-tetrahydro- 1 ,4-benzoxazepme 4-[(2-ethylpipeπdm-l-yl)carbonyl]-7-(2 -methyl- li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepme 4-({4-[2-(ethyloxy )phenyl]piperazm-l-yl}carbonyl)-7-(2 -methyl- l//-benzimidazol-6-yl)-2, 3,4, 5-tetrahydro- 1 ,4-benzoxazepme 3-(endo)-(hydroxymethyl)-8-{[7-(2 -methyl- 177-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)- yljcarbonyl} -8-azabicyclo[3.2.1 ]octan-3-ol 7-(2 -methyl- li/-benzimidazol-6-yl)-4-({4-[3-(tπfluoromethyl)phenyl]piperazin-l-yl}carbonyl)-2,3,4, 5- tetrahydro- 1 ,4-benzoxazepme 7-(2-methyl-l//-benzimidazol-6-yl)-4-({4-[2-(methyloxy)phenyl]piperazm-l-yl}carbonyl)-2,3,4,5-tetrahydro- 1 ,4-benzoxazepme ΛT-ethyl-7-(2 -methyl- li/-benzimidazol-6-yl)-iV-(pyridm-4-ylmethyl)-2,3-dihydro-l,4-benzoxazepme -4(5//)- carboxamide Λ?-methyl-5-(4-{[4-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4-benzoxazepm-7- yl)pyndme-2-carboxamide 4- { [2-(2-fluorophenyl)pipeπdin-l -yl]carbonyl} -7-(2 -methyl- 177-benzimidazol-6-yl)-2,3 ,4,5-tetrahydro- 1 ,4- benzoxazepme Λf-methyl-7-(2-methyl-l/f-benzimidazol-6-yl)-Λ r -[(15)-l-phenylethyl]-2,3-dihydro-l,4-benzoxazepme-4(5i/)- carboxamide 4-(4-{[7-(2-methyl-l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}piperazin-l- yl)phenol 7-(2-methyl-li/-benzimidazol-6-yl)-4-{[4-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepme 7-(2 -methyl- li/-benzimidazol-6-yl)-4-(octahydroqumohn-l(2i/)-ylcarbonyl)-2, 3, 4, 5 -tetrahydro- 1,4- benzoxazepme Λf-[(3Λ)-pyrrolidin-3-yl]-4-(4-{[4-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepm-7-yl)benzamide 7-(2-methyl-li/-benzimidazol-6-yl)-4-{[2-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepme (±)-(2/J,4iJ)-2-(4-fluorophenyl)- 1 - { [7-(2 -methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepin-4(5//)- yl] carbonyl } pipeπdm-4-ol 5-{4-[(4-methylpipeπdin-l-yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepm-7-yl}pyπdm-2-amme 1 - { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -4-phenylpipeπdme- 4-carbonitnle 4- { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5ij)-yl] carbonyl}piperazm-2-one 4-[(4-fluoropiperidm-l-yl)carbonyl]-7-(2 -methyl- l//-benzimidazol-6-yl)-2, 3, 4,5-tetrahydro-l,4-benzoxazepme 7-(l//-benzimidazol-6-yl)-4-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepine 7-(2 -methyl- li/-benzimidazol-6-yl)-4-[(2-{4-[(tπfluoromethyl)oxy]phenyl}pipeπdm-l-yl)carbonyl]-2, 3, 4,5- tetrahydro- 1 ,4-benzoxazepme 1 - { [7-(2-methyl- l//-benzirmdazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl}pipeπdme-4- carbonitπle 4-(7-azabicyclo[2.2.1]hept-7-ylcarbonyl)-7-(2-methyl-li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme 4-(4-bromophenyl)- 1 - {[7-(2 -methyl- 17f-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)- yl] carbonyl } pipeπdm-4-ol (l-{[7-(2 -methyl- l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carboπyl}pipeπdm-4- yl)methanol 7-[4-(l//-pyrazol-5-yl)phenyl]-4-{[4-(tnfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetraliydro-l,4- benzoxazepme 8- { [7-(2-methyl- l//-benzirmdazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -8- azabicyclo[3.2.1]octan-3-(exo)-ol 4-[(4,4-dimethylpipeπdm- 1 -yl) carbonyl] -7-(2-methyl- li/-benzimidazol-6-yl)-2, 3 ,4, 5-tetrahydro- 1 ,A- benzoxazepme 7-(2 -methyl- li/-benzimidazol-6-yl)-4-[(2-methylpiperidm-l-yl)carbonyl] -2,3,4, 5 -tetrahydro- 1,4 -benzoxazepme 7-(2-methyl-li/-benzimidazol-6-yl)-4-[(4-methylpipendm-l-yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepme 4-(4-chlorophenyl)- 1 - {[7-(2 -methyl- li/-benzimidazol-6-yl)-2,3-dihydro- 1 ,4-benzoxazepm-4(5//)- yl] carbonyl } pipeπdm-4-ol 4-methyl-l-{[7-(2-methyl-17/-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin-4(5//)-yl]carbonyl}pipeπdme- 4-carbonitπle 4-[4-chloro-3-(tπfluoromethyl)phenyl]-l-{[7-(2-methyl-l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm- 4 (5H) -yl] c arbonyl } pipeπdm-4 -ol 4-(2-azabicyclo[2 2.2]oct-2-ylcarbonyl)-7-(2-methyl-li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme 7-(2-methyl-li/-benzimidazol-6-yl)-4-{[4-(methylthio)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepme 7-(2 -methyl- li/-benzimidazol-6-yl)-4-({2-[4-(metliyloxy)phenyl]piperidm-l-yl}carbonyl)-2,3,4,5-tetrahydro- 1 ,4-benzoxazepme 6-(4-{[4-(difluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4-benzoxazepm-7-yl)-li/- benzimidazol-2 - amine 7-( l//-benzimidazol-6-yl)-4- {[4-(tπfluoromethyl)piperidm- 1 -yl] carbonyl} -2,3 ,4, 5-tetrahydro- 1 ,4- benzoxazepme 3-(l-{[7-(2-methyl-l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}piperidm-4- yl)propan- 1 -ol 5-(4-{[4-(tπfluoromethyl)piperidin-l-yl] carbonyl} -2, 3, 4,5-tetrahydro-l,4-benzoxazepin-7-yl)pyridm-2-amme 4- { [2-(3 ,4-dichlorophenyl)pipeπdm- 1 -yl] carbonyl} -7-(2-methyl- l//-benzrmidazol-6-yl)-2, 3 ,4, 5-tetrahydro- 1 ,A- benzoxazepme 4-({2-[3-fluoro-4-(methyloxy)phenyl]pipeπdm-l-yl}carbonyl)-7-(2 -methyl- li/-benzimidazol-6-yl)-2,3,4, 5- tetrahydro- 1 ,4-benzoxazepme 1 - { [7-(2-methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepin-4(5//)-yl] carbonyl} -4-phenylpipeπdin- 4-ol 7-(2 -methyl- li/-benzimidazol-6-yl)-4-[(4-propylpipendm-l -yl)carbonyl]-2,3,4,5-tetrahydro- 1 ,4-benzoxazeprne 8- { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -8- azabicyclo[3.2.1]octan-3-(endo)-ol 4-{[4-(2,2-difluoroethyl)pipeπdm-l-yl]carbonyl}-7-(2-methyl-li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme 8- { [7-(2-methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepm-4(5if)-yl] carbonyl} -8- azabicyclo[3.2.1]octan-3-one 4- {[4-(difluoromethyl)pipeπdm-l-yl]carbonyl}-7-(2 -methyl- 177-benzimidazol-6-yl)-2, 3, 4, 5-tetrahydro- 1,4- benzoxazepme 4-[(4-cyclopropylpipeπdin-l-yl)carbonyl]-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme 7-(2 -methyl- li/-benzimidazol-6-yl)-4- {[2-(4-methylphenyl)pipeπdm- 1 -yl] carbonyl} -2,3,4,5-tetrahydro- 1 ,A- benzoxazepme 4-(8-azabicyclo[3.2.1]oct-8-ylcarbonyl)-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme 2-(4-fluorophenyl)-l-({7-[4-(li/-imidazol-5-yl)phenyl]-2,3-dihydro-l,4-benzoxazepm-4(5i/)- yl} carbonyl)pipeπdm-4-one 4-[(4-ethylpipendm-l-yl)carbonyl]-7-(2 -methyl- li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine methyl (6-{4-[(3-(endo)-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl)carbonyl]-2,3,4,5-tetrahydro-l,4- benzoxazepm-7-yl}-l//-benzimidazol-2-yl)carbamate 1 - { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -4-[3- (methyloxy)phenyl]piperidm-4-ol 1 - { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5//)-yl] carbonyl} -4-(3- methylphenyl)piperidm-4-ol 7-(2 -methyl- li/-benzimidazol-6-yl)-4- {[4-( 1 -methylethyl)pipeπdm- 1 -yl]carbonyl} -2,3 ,4,5-tetrahydro- 1 ,4- benzoxazepme 7-[4-(5-fluoro-l//-benzimidazol-2-yl)phenyl]-4-{[4-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5- tetrahydro- 1 ,4-benzoxazepme 4-{[2-(4-chloroplienyl)pipeπdin-l-yl]carbonyl}-7-(2-methyl-l/f-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme 4- { [4-(fluoromethyl)pipeπdm- 1 -yl] carbonyl} -7-(2-methyl- l//-benzimidazol-6-yl)-2,3 ,4,5-tetrahydro- 1,4- benzoxazepme (±)-4- { [(25',4_R)-2,4-dimethylpipeπdin- 1 -yl] carbonyl} -7-(2 -methyl- l//-benzimidazol-6-yl)-2,3 ,4,5-tetrahydro- 1 ,4-benzoxazepme 8- { [7-(2-methyl- l//-benzirmdazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -3 -[3- (tπfluoromethyl)phenyl] -8-azabicyclo[3.2.1 ]octan-3 -(endo)-ol 4- { [3 -(e«(io)-(fluoromethyl)-8-azabicyclo[3.2.1 ]oct- 8 -yl] carbonyl} -7-(2-methyl- l//-benzimidazol-6-yl)- 2,3,4,5-tetrahydro-l,4-benzoxazepme 4-{[4-(l,l-difluoroethyl)piperidm-l-yl]carbonyl}-7-(2-methyl-li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme 8-{[7-(2-ammo-li/-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}-3-methyl-8- azabicyclo[3.2.1]octan-3-(endo)-ol 4-{[2-(4-chloro-3-fluorophenyl)pipeπdm-l-yl]carbonyl}-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5- tetrahydro- 1 ,4-benzoxazepme (±)-4-{[(25,45)-2,4-dimethylpipeπdm-l-yl]carbonyl}-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5-tetrahydro- 1 ,4-benzoxazepme 7-[4-(5-fluoro-l//-benzimidazol-2-yl)phenyl]-4-{[4-(fluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro- 1 ,4-benzoxazepme 7-(2-methyl-li/-benzimidazol-6-yl)-4-[(l-phenyl-3,4-dihydroisoqumolm-2(l//)-yl)carbonyl]-2,3,4,5- tetrahydro- 1 ,4-benzoxazepme 3-methyl-8-{[7-(2-methyl-l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}-8- azabicyclo[3.2.1]octan-3-(endo)-ol 4-(3 -fluorophenyl)- 1 - {[7-(2-methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepm-4(5//)- yl] carbonyl } pipeπdm-4-ol 1 - { [7-(2-methyl- l//-benzirmdazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -4- (trifluoromethyl)pipendm-4-ol 4-[(3-fluoro-3-(e«ύ?o)-methyl-8-azabicyclo[3.2.1]oct-8-yl)carbonyl]-7-(2 -methyl- l//-benzimidazol-6-yl)- 2,3,4,5-tetrahydro-l,4-benzoxazepme 4-(2-fluorophenyl)- 1 - {[7-(2 -methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepm-4(5//)- yl] carbonyl } pipeπdm-4-ol 4-(3 -chlorophenyl)- 1 - {[7-(2 -methyl- li/-benzimidazol-6-yl)-2,3-dihydro- 1 ,4-benzoxazepm-4(577)- yl] carbonyl } pipeπdm-4-ol 8-{[7-(2-methyl-l/f-imidazo[4,5-b]pyridm-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}-3- (trifluoromethyl)-8-azabicyclo[3.2.1]octan-3-(endo)-ol 4-[(3-(endo)-methyl-8-azabicyclo[3 2.1]oct-8-yl)carbonyl]-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5- tetrahydro- 1 ,4-benzoxazepme 5- {4-[(4-methylpipeπdm- 1 -yl)carbonyl]-2,3,4,5-tetrahydro-l ,4-benzoxazepm-7-yl} - 1 ,3-thiazol-2-amme 1 - { [7-(2-methyl- l/f-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -4-[3- (trifluoromethyl)phenyl]pipendm-4-ol 8- { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -3 -(tπfluoromethyl)- 8-azabicyclo[3.2.1]octan-3-(endo)-ol 5-(4- {[4-(tπfluoromethyl)pipeπdm- 1 -yl] carbonyl} -2,3 ,4,5-tetrahydro- 1 ,4-benzoxazepm-7-yl)- 1 ,3 -thiazol-2- amme, and (±)-[(2R,4S)- 1 - { [7-(2 -methyl- l//-benzimidazol-6-yl)-2,3-dmydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -2- phenylpiperidm-4 -yl] methanol optionally as a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition which comprises a compound, optionally as pharmaceutically acceptable salt thereof, of Claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent. 3. A method for treating a disease, disorder, or syndrome which method comprises administering to a patient a therapeutically effective amount of a compound of Claim 1, optionally as a pharmaceutically acceptable salt thereof, or administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 , optionally as a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent. 4. The method of Claim 3 where the disease is cancer. 5. The method of Claim 4 where the cancer is breast cancer, mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK- transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervical cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, colon cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreatic cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, glioblastoma, or head and neck cancer.","lang":"en","source":"WIPO_FULLTEXT","data_format":"ORIGINAL"}]},"claim_lang":["en"],"has_claim":true,"description":{"en":{"text":"BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE BACKGROUND OF THE INVENTION Field of the Invention [0001] This invention relates to the field of protein kinases and inhibitors thereof. In particular, the invention relates to inhibitors of mammalian target of rapamycin (mTOR) signaling pathways, and methods of their use. Background of the Invention [0002] The mammalian target of rapamycin, mTOR, is a protein kinase that integrates both extracellular and intracellular signals of cellular growth, proliferation, and survival. Extracellular mitogenic growth factor signaling from cell surface receptors and intracellular pathways that convey hypoxic stress, energy and nutrient status all converge at mTOR. mTOR exists in two distinct complexes: mTOR complex 1 (mTORCl) and mTOR complex 2 (mT0RC2). mTORCl is a key mediator of transcription and cell growth (via its substrates p70S6 kinase and 4E-BP1) and promotes cell survival via the serum and glucocorticoid-activated kinase SGK, whereas mTORC2 promotes activation of the pro-survival kinase AKT. Given its central role in cellular growth, proliferation and survival, it is perhaps not surprising that mTOR signaling is frequently dysregulated in cancer and other diseases (Bjornsti and Houghton Rev Cancer 2004, 4(5), 335- 48; Houghton and Huang Microbiol Immunol 2004, 279, 339-59; Inoki, Corradetti et al. Nat Genet 2005, 37(1), 19-24). [0003] mTOR is a member of the PIKK (PI3K-related Kinase) family of atypical kinases which includes ATM, ATR, and DNAPK, and its catalytic domain is homologous to that of PI3K. Dyregulation of PI3K signaling is a common function of tumor cells. In general, mTOR inhibition may be considered as a strategy in many of the tumor types in which PI3K signaling is implicated such as those discussed below. [0004] Inhibitors of mTOR may be useful in treating a number of cancers, including the following: breast cancer (Nagata, Lan et al., Cancer Cell 2004, 6(2), 117-27; Pandolfi N EnglJ Med 2004, 351(22), 2337-8; Nahta, Yu et al. Nat Clin Pract Oncol 2006, 3(5), 269-280); antle cell lymphoma (MCL) (Dal Col, Zancai et al. Blood 2008, 111(10), 5142-51); renal cell carcinoma (Thomas, Tran et al. Nat Med 2006, 12(1), 122-7; Atkins, Hidalgo et al. J Clin Oncol 2004, 22(5), 909-18; Motzer, Hudes et al. J Clin Oncol 2007, 25(25), 3958-64); acute myelogenous leukemia (AML) (Sujobert, Bardet et al.Blood 2005, 106(3), 1063-6; Billottet, Grandage et al. Oncogene 2006, 25(50), 6648-6659; Tamburini, EHe et al. Blood 2007, 110(3), 1025-8); chronic myelogenous leukemia (CML) (Skorski, Bellacosa et al. Embo J 1997, 16(20), 6151-61; Bai, Ouyang et al. Blood 2000, 96(13), 4319-27; Hickey and Cotter Biol Chem 2006, 281(5), 2441-50); diffuse large B cell lymphoma (DLBCL) (Uddin, Hussain et al. Blood 2006, 108(13), 4178-86); several subtypes of sarcoma (Hernando, Charytonowicz et al. Nat Med 2007, 13(6), 748-53; Wan and Helman Oncologist 2007, 12(8), 1007-18); rhabdomyosarcoma (Cao, Yu et al. Cancer Res 2008, 68(19), 8039-8048; Wan, Shen et al. Neoplasia 2006, 8(5), 394-401); ovarian cancer (Shayesteh, Lu et al. Nat Genet, 1999, 21(1), 99-102; (Lee, Choi et al. Gynecol Oncol 2005, 97(1) 26-34); endometrial tumors (Obata, Morland et al. Cancer Res 1998, 58(10), 2095-7; Lu, Wu et al. Clin Cancer Res 2008, 14(9), 2543-50); non small cell lung carcinoma (NSCLC) (Tang, He et al. Lung Cancer 2006, 51(2), 181-91; Marsit, Zheng et al. Hum Pathol 2005, 36(7), 768-76); small cell, squamous, large cell and adenocarcinoma (Massion, Taflan et al. Am JRespir Crit Care Med 2004, 170(10), 1088-94); lung tumors in general (Kokubo, Gemma et al. Br J Cancer 2005, 92(9), 1711-9; Pao, Wang et al. Pub Library of Science Med 2005, 2(1), el 7); colorectal tumors (Velho, Oliveira et al. Eur J Cancer 2005, 41(11), 1649-54; Foukas, Claret et al. Nature, 2006, 441(7091), 366-370), particularly those that display microsatellite instability (Goel, Arnold et al. Cancer Res 2004, 64(9), 3014-21; Nassif, Lobo et al. Oncogene 2004, 23(2), 617-28), KRAS-mutated colorectal tumors (Bos Cancer Res 1989. 49(17), 4682-9; Fearon ^rø N Y Acad Sd 1995, 768, 101-10); gastric carcinomas (Byun, Cho et al. Int J Cancer 2003, 104(3), 318-27); hepatocellular tumors (Lee, Soung et al. Oncogene 2005, 24(8), 1477-80); liver tumors (Hu, Huang et al. Cancer 2003, 97(8), 1929-40; Wan, Jiang et al. Cancer Res Clin Oncol 2003, 129(2), 100-6); primary melanomas and associated increased tumor thickness (Guldberg, thor Straten et al. Cancer Res 1997, 57(17), 3660-3; Tsao, Zhang et al. Cancer Res 2000, 60(7), 1800-4; Whiteman, Zhou et al. Int J Cancer2002, 99(1), 63-7; Goel, Lazar et al. J Invest Dermatol 126(1), 2006, 154-60); pancreatic tumors (Asano, Yao et al. Oncogene 2004, 23(53), 8571-80); prostate carcinoma (Cairns, Okami et al. Cancer Res 1997, 57(22), 4997-5000; Gray, Stewart et al. Br J Cancer 1998, 78(10), 1296-300; Wang, Parsons et al. Clin Cancer Res 1998, 4(3), 811-5; Whang, Wu et al. Proc Natl Acad Sd USA 1998, 95(9), 5246-50; Majumder and Sellers Oncogene 2005, 24(50) 7465-74; Wang, Garcia et al. Proc Natl Acad Sci USA 2006, 103(5), 1480-5; (Lu, Ren et al. Int J Oncol 2006, 28(1), 245-51; Mulholland, Dedhar et al. Oncogene 25(3), 2006, 329-37; Xin, Teitell et al. Proc Natl Acad Sci USA 72006, 03(20), 7789-94; Mikhailova, Wang et al. Adv Exp Med Biol 2008, 617, 397-405; Wang, Mikhailova et al. Oncogene 2008, 27(56), 7106-7117); thyroid carcinoma, particularly in the anaplastic subtype (Garcia-Rostan, Costa et al. Cancer Res 2005, 65(22), 10199-207); follicular thyroid carcinoma (Wu, Mambo et al. J Clin Endocrinol Metab 2005, 90(8), 4688-93); anaplastic large cell lymphoma (ALCL); hamaratomas, angiomyelolipomas, TSC-associated and sporadic lymphangioleiomyomatosis: Cowden's disease (multiple hamaratoma syndrome) (Bissler, McCormack et al. N EnglJ Med 2008, 358(2), 140-151); sclerosing hemangioma (Randa M. S. Amin Pathology International 2008, 58(1), 38-44); Peutz-Jeghers syndrome (PJS); head and neck cancer (Gupta, McKenna et al. Clin Cancer Res 2002, 8(3), 885-892); neurofibromatosis (F erner Eur J Hum Genet 2006, 15(2), 131-138; Sabatini Nat Rev Cancer 2006, 6(9), 729-734; Johannessen, Johnson et al. Current Biology 2008, 18(1), 56-62); macular degeneration; macular edema; myeloid leukemia; systemic lupus; and autoimmune lymphoproliferative syndrome (ALPS). SUMMARY OF THE INVENTION [0005] The following only summarizes certain aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and embodiments are described more fully below. All references cited in this specification are hereby incorporated by reference in their entirety. In the event of a discrepancy between the express disclosure of this specification and the references incorporated by reference, the express disclosure of this specification shall control. [0006] In view of the important role of mTOR in biological processes and disease states, the inventors realized that inhibitors of this protein kinase, including dual inhibitors mTORCl are desirable. Compounds of the Invention are potent and specific inhibitors of mTORCl . [0007] A first aspect of the invention provides a compound of Table 1, optionally as a pharmaceutically acceptable salt thereof. [0008] In a second aspect, the invention is directed to a pharmaceutical composition which comprises 1) a compound of Table 1 or a single stereoisomer or mixture of isomers thereof, optionally as a pharmaceutically acceptable salt or solvate thereof and 2) a pharmaceutically acceptable carrier, excipient, or diluent. [0009] In a third aspect of the invention is a method of inhibiting the in vivo activity of mTOR, the method comprising administering to a patient an effective mTOR-inhibiting amount of a compound of Table 1 or a single stereoisomer or mixture of isomers thereof, optionally as a pharmaceutically acceptable salt or solvate thereof or pharmaceutical composition thereof. [0010] In a fourth aspect, the Invention provides a method for treating a disease, disorder, or syndrome which method comprises administering to a patient a therapeutically effective amount of a compound of Table 1 or a single stereoisomer or mixture of isomers thereof, optionally as a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of Table 1 or a single stereoisomer or mixture of isomers thereof, optionally as a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient, or diluent. DETAILED DESCRIPTION OF THE INVENTION Abbreviations and Definitions The following abbreviations and terms have the indicated meanings throughout: Abbreviation Meaning [0012] \"Administration\" and variants thereof (e.g., \"administering\" a compound) in reference to a compound of the invention means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment. When a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., surgery, radiation, and chemotherapy, etc.), \"administration\" and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents. [0013] \"Yield\" for each of the reactions described herein is expressed as a percentage of the theoretical yield. [0014] \"Metabolite\" refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, \"The Pharmacological Basis of Therapeutics\" 8.sup.th Ed., Pergamon Press, Gilman et al. (eds), 1990 for a discussion of biotransformation). As used herein, the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body. In one example, a prodrug may be used such that the biologically active form, a metabolite, is released in vivo. In another example, a biologically active metabolite is discovered serendipitously, that is, no prodrug design per se was undertaken. An assay for activity of a metabolite of a compound of the present invention is known to one of skill in the art in light of the present disclosure. [0015] \"Patient\" for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a specific embodiment the patient is a mammal, and in a more specific embodiment the patient is human. [0016] A \"pharmaceutically acceptable salt\" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington 's Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference or S. M. Berge, et al., \"Pharmaceutical Salts,\" J. Pharm. Sci., 1977;66: 1-19 both of which are incorporated herein by reference. [0017] Examples of pharmaceutically acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3- hydroxy-2-ene- 1 -carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p-toluenesulfonic acid, and salicylic acid and the like. [0018] Examples of a pharmaceutically acceptable base addition salts include those formed when an acidic proton present in the parent compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Specific salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tromethamine, N-methylglucamine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.\"Platin(s),\" and \"platin-containing agent(s)\" include, for example, cisplatin, carboplatin, and oxaliplatin. [0019] \"Prodrug\" refers to compounds that are transformed (typically rapidly) in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. Common examples include, but are not limited to, ester and amide forms of a compound having an active form bearing a carboxylic acid moiety. Examples of pharmaceutically acceptable esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons) the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl. Examples of pharmaceutically acceptable amides of the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons). Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, \"Pro-drugs as Novel Delivery Systems,\" VoI 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes. [0020] \"Therapeutically effective amount\" is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a \"therapeutically effective amount\" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their knowledge and to this disclosure. [0021] \"Treating\" or \"treatment\" of a disease, disorder, or syndrome, as used herein, includes (i) preventing the disease, disorder, or syndrome from occurring in a human, i.e. causing the clinical symptoms of the disease, disorder, or syndrome not to develop in an animal that may be exposed to or predisposed to the disease, disorder, or syndrome but does not yet experience or display symptoms of the disease, disorder, or syndrome; (ii) inhibiting the disease, disorder, or syndrome, i.e., arresting its development; and (iii) relieving the disease, disorder, or syndrome, i.e., causing regression of the disease, disorder, or syndrome. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art. Embodiments of the Invention [0022] Another embodiment provides a pharmaceutical composition which comprises 1) a compound, as a single stereoisomer or mixture of isomers thereof, selected from Table 1 , optionally as a pharmaceutically acceptable salt thereof, and 2) a pharmaceutically acceptable carrier, excipient, and/or diluent thereof. [0023] Another embodiment is a method of treating disease, disorder, or syndrome where the disease is associated with uncontrolled, abnormal, and/or unwanted cellular activities effected directly or indirectly by mTOR which method comprises administering to a human in need thereof a therapeutically effective amount of a Compound selected from Table 1 , optionally as a pharmaceutically acceptable salt or pharmaceutical composition thereof. In another embodiment the disease is cancer. [0024] Embodiment (A): Another embodiment is directed to a method of treating a disease, disorder, or syndrome which method comprises administering to a patient a therapeutically effective amount of a Compound selected from Table 1, optionally as a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a Compound selected from Table 1 , and a pharmaceutically acceptable carrier, excipient, or diluent. In another embodiment the disease is cancer. [0025] In another embodiment of any of the embodiments of Embodiment (A), the cancer is breast cancer, mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK-transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervical cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, colon cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreatic cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, glioblastoma, or head and neck cancer. Representative Compounds [0026] Compoudns of the Invention are depicted below. In each instance the embodiment includes both the recited compounds, as well as a single stereoisomer or mixture of stereoisomers thereof, as well as a pharmaceutically acceptable salt thereof. Compounds of the invention are named according to systematic application of the nomenclature rules agreed upon by the International Union of Pure and Applied Chemistry (IUPAC), International Union of Biochemistry and Molecular Biology (IUBMB), and the Chemical Abstracts Service (CAS) Specifically, names in Table 1 were generated using ACD/Labs naming software 8.00 release, product version 8.08 or later. [0027] In one embodiment, the invention comprises compounds of structural formula wherein the combination of R 1 and R 2 are as defined in one of the compounds in Table 1, below, and pharmaceutically acceptable salts thereof. [0028] In another embodiment, the invention comprises a compound in Table 1, and pharmaceutically acceptable salts thereof. Table 1 1 - -yl] c arbonyl } - } - ,4,5- } - } - pyπdm-2 - - 7 - (2- {4- - } - - 7 -(2 - IH- 1 - {[7-(2- 1 ,4- 3 ,4 , 5 - amine } - - - - - 7 -(2 - 5- ,4 , 5 - -ol - -yl] carbonyl } - -7- - 1 - - 1 - -(endo)- XH- IH- XH- - ,3-thiazol- General Administration [0029] In one aspect, the invention provides pharmaceutical compositions comprising an inhibitor of mTOR according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent. In certain other specific embodiments, administration is by the oral route. Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, specifically in unit dosage forms suitable for simple administration of precise dosages. [0030] The compositions will include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include carriers and adjuvants, etc. [0031] Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. [0032] If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene, etc. [0033] The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability. [0034] Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. [0035] One specific route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated. [0036] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. [0037] Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients. [0038] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifϊers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension. [0039] Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like. [0040] Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non- irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein. [0041] Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention. [0042] Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. [0043] Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and 99% to 1 % by weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients. [0044] Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention. [0045] The compounds of the invention, or their pharmaceutically acceptable salts or solvates, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy. The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art. [0046] If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate. General Synthesis [0047] Compounds of this invention can be made by the synthetic procedures described below. The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis.), or Bachem (Torrance, Calif.), or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4 Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure. The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data. [0048] Unless specified to the contrary, the reactions described herein take place at atmospheric pressure and over a temperature range from about -78 0 C to about 150 0 C, more specifically from about 0 0 C. to about 125 0 C and more specifically at about room (or ambient) temperature, e.g., about 20 0 C. Unless otherwise stated (as in the case of an hydrogenation), all reactions are performed under an atmosphere of nitrogen. [0049] Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups regenerate original functional groups by routine manipulation or in vivo. Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, \"Pro-drugs as Novel Delivery Systems,\" VoI 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes. [0050] The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms or quaternized nitrogen atoms in their structure. Compounds of the Invention that may be prepared through the syntheses described herein may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention. [0051] Some of the compounds of the invention contain an active ketone -C(O)CF3 and may exist in part or in whole as the -C(OH 2 )CF 3 form. Regardless of whether the compound is drawn as the -C(O)CF 3 or -C(OH 2 )CF 3 form, both are included within the scope of the Invention. Although an individual compound may be drawn as the -C(O)CF 3 form, one of ordinary skill in the art would understand that the compound may exist in part or in whole as the -C(OH 2 )CFs form and that the ratio of the two forms may vary depending on the compound and the conditions in which it exists. [0052] Some of the compounds of the invention may exist as tautomers. For example, where a ketone or aldehyde is present, the molecule may exist in the enol form; where an amide is present, the molecule may exist as the imidic acid; and where an enamine is present, the molecule may exist as an imine. All such tautomers are within the scope of the invention. Further, for example, in this application R 1 can be 5-oxo-lH-l,2,4-triazol-3-yl, depicted structurally below: 100. Both 5-oxo-lH-l,2,4-triazol-3-yl and the above structure 1 include, and are equivalent to, 3-hydroxy-4H-l,2,4-triazol-5-yl and its structure 2: 200. Regardless of which structure or which terminology is used, each tautomer is included within the scope of the Invention. [0053] The present invention also includes N-oxide derivatives and protected derivatives of compounds of the Invention. For example, when compounds of the Invention contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. When compounds of the Invention contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable \"protecting group\" or \"protective group\". A comprehensive list of suitable protective groups can be found in T.W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. 1991, the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of the Invention can be prepared by methods well known in the art. [0054] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specifϊc reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystallization. [0055] In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention. [0056] The chemistry for the preparation of the compounds of this invention is known to those skilled in the art. In fact, there may be more than one process to prepare the compounds of the invention. The following examples illustrate but do not limit the invention. All references cited herein are incorporated by reference in their entirety. Synthetic Examples Reagent Preparation 1 2-(4-chloro-3-fluorophenyl)piperidine [0057] STEP 1 : To a solution of tert-butyl 2-oxopiperidine- 1 -carboxylate (0.22 g, 1.08 mmol) in tetrahydrofuran (5 mL) at -78 0 C was added slowly over 15 minutes 4-chloro-3- fluorophenylmagnesium bromide (0.5 M in tetrahydrofuran) (2.60 mL, 1.66 mmol) and the mixture was allowed to warm to 25 °C over 30 minutes. The reaction mixture was quenched by the addition of 1.0 N hydrochloric acid (1.0 mL) and partitioned with diethyl ether (50 mL). The organic layer was separated and washed with brine (25 mL), dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (diethyl ether/hexanes 1 :4) to give tert-butyl 5-oxo-5-(4-chloro3-fluorophenyl)pentylcarbamate (0.25 g, 70% yield). 1 H NMR (400 MHz, CDCl 3 ): 7.73 (dd, IH), 7.69 (m, IH), 7.50 (dd, IH), 4.59 (brs, IH), 3.18 (m, 2H) 2.97 (t, 2H), 1.77 (m, 2H), 1.57 (m, 2H), 1.44 (s, 9H). MS (EI) for Ci 6 H 2 IFClNO 3 : 330 (MH + ). [0058] STEP 2: A solution of tert-butyl 5-oxo-5-(4-chloro-3-fluorophenyl)pentylcarbamate (0.25 g, 0.76 mmol) was stirred in trifluoroacetic acid (1.5 mL) for 1 hour then concentrated. The residue was partitioned between dichloromethane (40 mL) and 2 M aqueous sodium hydroxide (20 mL). The organic layer was separated and washed with brine (20 mL), dried over anhydrous magnesium sulfate filtered and concentrated to provide 5-amino-l-(4-chloro-3- fluorophenyl)pentan-l-one. To a solution of the crude product in a mixture of methanol (50 mL) and water (0.5 mL) was added sodium borohydride (43 mg, 1.14 mmol) and stirred for 16 hours at room temperature. The reaction mixture was quenched by the addition of IM aqueous hydrochloric acid (1.0 mL) and concentrated. The residue was partitioned between dichloromethane (100 mL) and saturated aqueous sodium hydrogencarbonate (20 mL), washed with brine (20 mL), filtered and concentrated to give 2-(4-chloro-3-fluorophenyl)piperidine (0.14 g, 85% yield) as an oil. [0059] Using analogous techniques and substituting alternative reagents in step 1 the following reagents were prepared. All starting materials were commercially obtained unless otherwise stated. [0060] 2-(4-chlorophenyl)piperidine. Synthesized according to the method of reagent preparation 1 using 4-chlorophenylmagnesium bromide in step 1. MS (EI) for C H H H CIN: 196 (MH + ). [0061] 2-(4-(trifluoromethoxy)phenyl)piperidine. Synthesized according to the method of reagent preparation 1 using 4-trifluoromethoxyphenylmagnesium bromide in step 1. MS (EI) for Ci 2 Hi 4 F 3 NO: 246 (MH + ). [0062] 2-(3-fluoro-4-methoxyphenyl)piperidine. Synthesized according to the method of reagent preparation 1 using 3-fluoro-4-methoxyphenylmagnesium bromide in step 1. MS (EI) for Ci 2 Hi 6 FNO: 210 (MH + ). [0063] 2-(2-fluorophenyl)piperidine. Synthesized according to the method of reagent preparation 1 using 2-fluorophenylmagnesium bromide in step 1. MS (EI) for C 11 H 14 FN: 180 (MH + ). [0064] 2-(3,4-dichlorophenyl)piperidine. Synthesized according to the method of reagent preparation 1 using 3,4-dichlorophenylmagnesium bromide in step 1. MS (EI) for C H H I3 CI 2 N: 230 (MH + ). Reagent Preparation 2 (±)-(2 J ff,45)-2-pheny]piperidin-4-ylmethanol [0065] STEP 1 : A suspension of potassium tert-butoxidc (1.25 g, 11.1 mmol) and methyltriphenylphosphonium bromide (3.86 g, 1.1 mmol) in tetrahydrofuran (100 mL) was stirred at 40 0 C for 30 minutes. The mixture was then cooled to room temperature and a solution of tert-butyl 4-oxo-2-phenylpiperidine-l-carboxylate (2.35 g, 8.5 mmol) in tetrahydrofuran (30 mL) was added slowly. The reaction mixture was stirred at 40 0 C for 24 hours. The mixture was cooled to room temperature and quenched by the addition of water and diluted with ethyl acetate (250 mL), The organic layer was separated then washed with water, 10% aqueous citric acid and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography on silica gel (hexane:ethyl acetate 95:5 to 9:1) provided tert-butyl 4-methylene-2- phenylpiperidine-1-carboxylate (2.24 g, 96%). 1 H NMR (400 MHz, CDCl 3 ): 7.31 (m, 4H), 7.21 (m, IH), 5.48 (br d, IH), 4.84 (dd, 2H), 4.07 (br dd, IH), 2.85 (br, t, IH), 2.78 (dtr, IH), 2.64 (dd, IH), 2.28 (dtr, IH), 2.20 (br d, IH), 1.42 (s, 9H). GC/MS (EI) for C n H 23 NO 2 : 273 (M + ). [0066] STEP 2: To solution of tert-butyl 4-methylene-2-phenylpiperidine-l-carboxylate (2.20 g, 8.04 mmol) in tetrahydrofuran (50 mL) at 0 0 C was added borane-tetrahydrofuran complex (IM solution in in tetrahydrofuran) (12.1 mL, 12.1 mmol) and the reaction mixture was stirred at 0 0 C for 1 hour. The reaction mixture was allowed to warm to room temperature then stirred for an additional 2 hours. It was cooled to 0 0 C and 2M aqueous sodium hydroxide (8.0 mL, 16.0 mmol) was added slowly followed by the slow addition of 30% aqueous hydrogen peroxide (5.5 mL, 48.4 mmol). The mixture was stirred for another hour then diluted with water (100 mL) and partitioned with ethyl acetate (250 mL). The organic layer was separated and washed with 2M aqueous sodium thiosulfate (100 mL), brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography in silica gel (chlorofornrmethanol 9:1 to 4:1) provided tert-butyl 4-(hydroxymethyl)-2-phenylpiperidine-l-carboxylate (1.86 g, 79%). 1 H NMR (400 MHz, CDCl 3 ): 7.30 (m, 2H), 7.20 (m, 3H), 4.86 (dd, IH), 4.04 (m, IH), 3.62 (m, 0.5H), 3.44 (m, 3H), 3..24 (m, IH), 2.12 (m, 0.5H), 1.93(m, IH), 1.64 (m, 2H), 1.42 (m, IH), 1.26 (s, 9H). GC/MS (EI) for Ci 7 H 25 NO 3 : 235 (M-tBu + ). [0067] STEP 3 : To a solution of tert-butyl 4-(hydroxymethyl)-2-phenylpiperidine- 1 - carboxylate (0.29 g, 1.00 mmol) in dichloromethane (50 mL) was added trifluoroacetic acid (10 mL) and the reaction mixture was heated to reflux. After cooling to room temperature the solvent was evaporated. The residue was twice taken into 50% ethyl acetate in toluene then concentrated (2x100 mL) and the resulting solid then dried to give (±)-(2R,4S)-2- phenylpiperidin-4-ylmethanol as the trifluoroacetic acid salt (0.26 g, quantitative). MS (EI) for Ci 2 Hi 7 NO: 192 (MH + ). Reagent Preparation 3 2-(trifluoromethyl)piperidine [0068] A mixture of 2-(trifluoromethyl)pyridine (0.38 g, 2.60 mmol) and platinum oxide (0.04 g, 0.18 mmol) in acetic acid (15 mL) and concentrated hydrochloric acid (2 mL) was hydrogenated in a Parr apparatus at 40 psi for 3 d. Filtration through celite and concentration of the filtrate provided 2-(trifluoromethyl)piperidine as hydrochloride salt which was used without further purification. 1 H NMR (400 MHz, methanol-d 4 ): 4.18 (m, IH), 3.50 (m, IH), 3.15 (m, IH), 2.16 (m, IH), 1.99 (m, 2H), 1.71 (m, 3H). [0069] Using analogous synthetic techniques and substituting with alternative starting reagents the following reagents were prepared. Alternative starting materials were obtained commercially unless otherwise indicated. [0070] 4-cyclopropylpiperidine. Prepared as hydrochloride salt according to reagent preparation 3 by using 4-cyclopropylpyridine. MS (EI) for C 8 Hi 5 N: 125 (M + ). Reagent Preparation 4 4-(difluoromethy])piperidine [0071] STEP 1 : To a solution of tert-butyl (4-hydroxymethyl)piperidine-l-carboxylate (0.52 g, 2.40 mmol, (J. Labelled Compounds and Radiopharmaceuticals 1999, 42, 1289-1300) in dichloromethane (20 mL) was added Dess-Martin-periodinane (1.13 g, 2.66 mmol), and the mixture was stirred at room temperature for 2 h. A 10% aqueous solution of sodium thiosulfate (20 mL) was added followed by saturated sodium bicarbonate (20 mL), and the biphasic mixture was stirred at room temperature for 45 min. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x). The combined organic layers were washed with saturated sodium bicarbonate, brine, dried over sodium sulfate then filtered and concentrated to afford tert-butyl 4-formylpiperidine-l-carboxylate. 1 H NMR (400 MHz, CDCl 3 ): 9.67 (s, IH), 3.99 (m, 2H), 2.93 (m, 2H), 2.42 (m, IH), 1.89 (m, 2H), 1.55 (m, 2H), 1.46 (s, 9H). [0072] STEP 2: To a solution of DAST (1.16 g, 7.20 mmol) in dichloromethane (30 mL) was added a solution of tert-butyl 4-formylpiperidine-l-carboxylate (0.51 g, 2.40 mmol) in dichloromethane (5 mL) at 0 0 C. The reaction mixture was warmed to room temperature and stirred for 18 h. A 5% aqueous solution of sodium bicarbonate was added, the layers were separated, the organic layer was washed with saturated sodium bicarbonate, and brine, dried over sodium sulfate, filtered and concentrated to provide tert-butyl 4-(difiuoromethyl)piperidine-l- carboxylate. 1 H NMR (400 MHz, CDCl 3 ): 5.59 (m, IH), 4.20 (m, 2H), 2.69 (m, 2H), 1.91 (m, IH), 1.74 (m, 2H), 1.46 (s, 9H), 1.34 (m, 2H). [0073] STEP 3: A solution of tert-butyl 4-(difluoromethyl)piperidine- 1 -carboxylate in trifluoroacetic acid was stirred at room temperature for 1 h then concentrated and dried to give 4-(difluoromethyl)piperidine as the trifluoroacetate salt. 1 H NMR (400 MHz, CDCl 3 ): 5.67 (m, IH), 3.55 (m, 2H), 2.96 (m, 2H), 2.04 (m, 3H), 1.80 (m, 2H). Reagent Preparation 5 4-(fluoromethyl)piperidine [0074] A solution of tert-butyl 4-(fluoromethyl)piperidine-l -carboxylate (J. Labelled Compounds and Radiopharmaceuticals 1999, 42, 1289-1300) in trifluoroacetic acid was stirred at room temperature for 1 h and then concentrated and dried to give 4-(fluoromethyl)-piperidine as the trifluoroacetate salt. 1 H NMR (400 MHz, CDCl 3 ): 4.33 (dd, 2H), 3.49 (m, 2H), 2.92 (m, 2H), 2.07 (m, IH), 1.97 (m, 2H), 1.64 (m, 2H). Reagent Preparation 6 4-(l,l-difluoroethyl)piperidine [0075] STEP 1 : To a solution of DAST (1.83 g, 11.35 mmol) in dichloromethane (30 mL) was added 4-acetylpyridine (1.00 g, 8.25 mmol) at 0 0 C. The reaction mixture was warmed to room temperature and stirred for 2 d. More DAST (0.61 g, 3.78 mmol) was added and stirring was continued for 1 d. A 5% aqueous solution of sodium bicarbonate was added, the layers were separated and the organic layer was washed with saturated sodium bicarbonate, and brine then dried over sodium sulfate, filtered and concentrated to provide a 5: 1 mixture of 4-(l ,1- difluoroethyl)pyridine and 4-acetylpyridine. [0076] STEP 2: The mixture was dissolved in methanol (10 mL) and 1 M hydrochloric acid (10 mL) then catalytic platinum oxide was added and the resulting suspension was hydrogenated in a Parr apparatus at 40 psi for 3 d. Filtration through celite and concentration of the filtrate gave a complex mixture containing 20% of the desired 4-(l,l-difluoroethyl)piperidine as the hydrochloride salt which was used without further purification. Reagent Preparation 7 4-(methylthio)piperidine [0077] STEP 1 : To a solution of tert-butyl 4-hydroxypiperidine- 1 -carboxylate (4.0 g, 20.0 mmol) and triethylamine (4.0 g, 40 mmol) in dichloromethane (50 mL) was added methanesulfonyl chloride (2.8 g, 24.4 mmol) at 0 0 C. The solution was stirred at 0 0 C for 10 min, then at room temperature for 2 h. The reaction mixture was partitioned between 10% citric acid and ethyl acetate. The organic layer was washed with sodium bicarbonate, and brine, dried over sodium sulfate, filtered and concentrated to give tert-butyl 4- (methylsulfonyloxy)piperidine- 1 -carboxylate (6.4 g, quantitative yield). MS (EI) for CnH 2I NO 5 S: 279 (M + ). [0078] STEP 2: A solution of tert-butyl 4-(methylsulfonyloxy)piperidine- 1 -carboxylate (2.0 g, 7.2 mmol) and sodium thiomethoxide (1.0 g, 14.4 mmol) in methanol (30 mL) was refluxed for 15 h and then concentrated. The residue was partitioned between water and ethyl acetate. The aqueous layer was extracted twice with ethyl acetate and the combined organic extracts washed with brine, dried over sodium sulfate, filtered and concentrated. Column chromatography on silica (3% ethyl acetate in hexanes) afforded tert-butyl 4- (methylthio)piperidine- 1 -carboxylate (0.98 g, 58% yield) as a colorless oil. MS (EI) for CnH 21 NO 2 S: 231 (M + ). [0079] STEP 3: A solution of tert-butyl 4-(methylthio)piperidine-l -carboxylate (63 mg, 0.27 mmol) in methanol (1 mL) and 4 N hydrogen chloride in dioxane (4 mL) was refluxed for 2 min and then concentrated and dried to provide 4-(methylthio)piperidine hydrochloride as a colorless oil. Reagent Preparation 8 3-(trifluoromethyl)-8-azabicyclo [3.2.1] octan-3-(endo)-ol [0080] Step 1 : Trimethyl(trifluoromethyl)silane (0.32 g, 2.25 mmol) was added to a mixture of tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (0.50 g, 2.2 mmol), cesium carbonate (1.1 g, 3.4 mmol) in N,N-dimethylformamide (5 mL) at O 0 C. The resulting mixture was warmed to room temperature and stirred for two hours. The mixture was diluted with ethyl acetate (80 mL), washed with water (3 x 50 mL) then brine (50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was taken into methanol (20 mL) and potassium carbonate (0.62 g, 4.5 mmol) was added then stirred at room temperature for 18 hours. The mixture was diluted with ethyl acetate (150 mL) then filtered and concentrated. The residue was purified by silica gel chromatography (10% to 25% ethyl acetate in hexanes gradient) to give tert-butyl 3-(endo)-hydroxy-3-(trifluoromethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (0.36 g, 55% yield), GC-MS (EI) for Ci 3 H 20 F 3 NO 3 : 295 (M + ). [0081] Step 2: tert-Butyl 3-(enJo)-hydroxy-3-(trifluoromethyl)-8-azabicyclo[3.2.1]octane-8- carboxylate 1 (0.36 g, 1.2 mmol) was taken into acetonitrile (2 mL) and 4 M hydrogen chloride in 1 ,4-dioxane (2 mL) then stirred at 70 0 C for 15 minutes. The reaction mixture was concentrated and dried to give 3-(trifluoromethyl)-8-azabicyclo[3.2.1]octan-3-(e«ύfo)-ol hydrochloride (0.28g, 100% yield). MS (EI) for C 8 H 12 F 3 NO: 196 (MH + ). Reagent Preparation 9 3-methyl-8-azabicyclo [3.2.1 ] octan-3-(endo)-o\\ [0082] Step 1 : Methylmagnesium bromide (3 M solution in ether, 2.7 mmol) was added to a solution of tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (0.50 g, 2.2 mmol), in tetrahydrofuran (20 mL) at 0 0 C and the resulting mixture was stirred one hour. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (20 mL) then partitioned with ethyl acetate (80 mL). The organic portion was separated, washed with water, then brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (5% to 35% ethyl acetate in hexanes gradient) to give tert-butyl 3-(endo)-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate (0.22 g, 41% yield), GC- MS (EI) for Ci 3 H 23 NO 3 : 241 (M + ). [0083] Step 2: tert-Butyl 3-(endo)-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8- carboxylate (0.22 g, 1.2 mmol) was taken into acetonitrile (1 mL), and 4 M hydrogen chloride in 1,4-dioxane (1 mL) then stirred at 70 0 C for 15 minutes. The reaction mixture was concentrated and dried to give 3-methyl-8-azabicyclo[3.2. l]octan-3-(endo)-ol hydrochloride salt (0.16 g, 100% yield). MS (EI) for C 8 H 12 F 3 NO: 142 (MH + ). Reagent Preparation 10 3-fluoro-3-(e«rfo)-methyl-8-azabicyclo [3.2.1] octane [0084] Step 1 : Dimethylaminosulfur trifluoride (81 mg, 0.61 mmol) was added to a solution of tert-butyl 3-(e/?]pyridine. [00117] STEP 1 : To a solution of 6-bromo-2-methyl- lH-imidazo[4,5-6]pyridme (3.8 g, 17.5 mmol) in dimethylformamide (20 mL) at 0 0 C was added 60% sodium hydride in mineral oil (1.05 g, 26.2 mmol) and the reaction mixture was stirred for 30 minutes, followed by the addition of a solution of triphenylmethyl chloride (5.4 g, 19.4 mmol) in dimethylformamide (10 mL). The reaction mixture was stirred at room temperature for 16 hours then it was quenched by the careful addition of water and diluted with ethyl acetate (450 mL), washed with 10% aqueous citric acid (2 x 100 mL), brine (250 mL), dried over anhydrous sodium sulfate and concentrated. Column chromatography (hexane ethyl acetate 9:1 to 4: 1) provided 6-bromo-2 -methyl- 1- (triphenylmethyl)-lH-imidazo[4,5-έ]pyridine (0.51 g, 6%). 1 H NMR (400 MHz, CDCl 3 ): 7.99 (d, IH), 7.96 (d, IH), 7.33-7.23 (m, 15H), 2.00 (s, 3H). MS (EI) for C 26 H 20 BrN 3 : 454 (MH + ). Reagent Preparation 21 1,1-dimethylethyl 7-bromo-2,3-dihydro-l,4-benzoxazepine-4(5H)-carboxylate [00118] STEP 1 : Commercially-available 5-bromo-2-hydroxybenzaldehyde (4.0 g, 10 mmol) and 2-aminoethanol were combined in THF/MeOH (100 mL, 10:1) and sodium borohydride (0.76 g, 2.0 mmol) was added with stirring. The resulting reaction mixture was stirred at 40 0 C for 4 h, concentrated on a rotary evaporator then diluted with EtOAc (50 mL) and saturated NaHCO 3 (30 mL). To this suspension was added di-tert-buty\\ dicarbonate (2.83 g, 13 mmol). The mixture was stirred at rt overnight. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated on a rotary evaporator. Hexane was subsequently added to the crude reaction product which resulted in the formation of a white solid. This slurry was filtered to obtain ter£-butyl-5-bromo-2-hydroxybenzyl(2- hydroxyethyl)carbamate (6.8 g, 98 %) as a white solid. MS (EI) for Ci 4 H 20 BrNO 4 , found 346 (MH + ). [00119] STEP 2: terϊ-Butyl-5-bromo-2-hydroxybenzyl(2-hydroxyethyl)carbamate (3.46 g, 10 mmol) and triphenylphosphine (3.96 g, 15 mmol) were combined in DCM (100 mL) and diisopropyl azodicarboxylate (3.03 g, 15 mmol) was added. The resulting reaction mixture was stirred at rt for 12 h. The reaction mixture was washed with water, dried, filtered, and concentrated on a rotary evaporator. The resulting crude product was purified via silica gel chromatography eluting with 8:2 hexane/ethyl acetate to give the desired product (1.74 g, 53 %) as a white solid. MS (EI) for Ci 4 Hi 8 BrNO 3 , found 328 (MH + ). Reagent Preparation 22 4-(2,2-difluoroethyl)piperidine [00120] STEP 1 : To a solution of ter£-butyl 4-(2-hydroxyethyl)piperidine-l-carboxylate (0.6 g, 2.6 mmol) in dichloromethane (30 mL) was added Dess-Martin-periodinane (1.2 g, 2.8 mmol), and the mixture was stirred at room temperature for 90 min. A 10% aqueous solution of sodium thiosulfate (15 mL) was added followed by saturated sodium bicarbonate (15 mL), and the biphasic mixture was stirred at room temperature for 1 h. The layers were separated, the aqueous layer was extracted twice with dichloromethane. The combined organic layers were washed with saturated sodium bicarbonate, and brine, dried over sodium sulfate,fϊltered and concentrated to afford tert-butyl 4-(oxoethyl)piperidine-l-carboxylate that was used directly without further purification [00121] STEP 2: To a solution of tert-butyl 4-(oxoethyl)piperidine-l-carboxylate as obtained in step 1 in dichloromethane (50 mL) was added DAST (1.2 g, 7.8 mmol) at 0 0 C. The reaction mixture was warmed to room temperature and stirred for 17 h. A 5% aqueous solution of sodium bicarbonate was added and the layers were separated. The organic layer was washed with saturated sodium bicarbonate, and brine, dried over sodium sulfate, filtered and concentrated to provide tert-butyl 4-(2,2-difiuoroethyl)piperidine-l-carboxylate that was used directly without further purification. [00122] STEP 3: tert-Butyl 4-(2,2-difluoroethyl)piperidine-l-carboxylate as obtained in step 2 was dissolved in a minimum of trifiuoroacetic acid and the resulting solution was stirred at room temperature for 2 h. The solution was then concentrated to give 4-(2,2- difluoroethyl)piperidine as the trifluoroacetate salt. MS (EI) for C 7 Hi 3 F 2 N: 150 (MH + ). Synthetic Example 1 4-{[2-(4-chlorophenyl)piperidin-l-yl]carbonyl}-7-(2-methyl-lH-benzimidazol-6-yl)-2,3,4,5- tetrahydro-l,4-benzoxazepine [00123] STEP 1 : To 5-bromo-2-methylbenzimidazole (38 g, 180 mmol) in TΗF (400 mL) was added di-tert-butyl dicarbonate (39 g, 189 mmol). The reaction mixture was stirred at room temperature for 24 h and then concentrated. Ethyl acetate (400 mL) was added to the residue, and the solution was washed with 10% aqueous citric acid (2 x 100 mL), water (100 mL), and brine (100 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (gradient 20-30% ethyl acetate in hexane) provided 1,1 -dimethyl 6-bromo-2-methyl-lH- benzimidazole-1-carboxylate (27 g, 48% yield) as a beige solid. MS (EI) for Ci 3 Hi 5 BrN 2 O 2 : 312 (MH + ) [00124] STEP 2: A solution of 1,1-dimethylethyl 7-bromo-2,3-dihydro-l,4-benzoxazepine- 4(5H)-carboxylate (reagent preparation 21) (30.0 g, 91.4 mmol) and triisopropyl borate (22.4 g, 119 mmol) in THF (300 mL) was cooled to -78 0 C, and a 2.5M solution of n-butyllithium in hexanes (47.6 mL, 119 mmol) was added dropwise over 40 min at this temperature. The reaction mixture was stirred at -78 0 C for an additional 30 min, then quenched by dropwise addition of 2 N hydrochloric acid (80 ml), and allowed to warm up to room temperature. Ethyl acetate (100 mL) and water (100 mL) were added, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organic layers were washed with water, dried over sodium sulfate, and concentrated. Hexane (200 mL) was added to the residue and the mixture was stirred overnight. The precipitate was filtered, washed several times with hexane, and dried to give (4-{[(l,l-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro- 1 ,4-benzoxazepin-7-yl)boronic acid (23.4g, 87%) as a colorless solid. MS (EI) for Ci 4 H 20 BNO 5 : 294 (MH + ). [00125] STEP 3: A suspension of 1,1 -dimethylethyl 6-bromo-2-methyl-lH-benzimidazole-l- carboxylate (11.3 g, 36 mmol), (4-{[(l,l-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepin-7-yl)boronic acid (11.7 g, 40 mmol), dichloro[l,l-bis(diphenyl- phosphino]ferrocenepalladium (II) dichloromethane adduct (3.0 g, 10 mol %) in dioxane (115 mL) and water (28.5 mL) was degassed with nitrogen, and then diisopropylethylamine (18.6 g, 144 mmol) was added. The reaction mixture was stirred at 90 0 C for 220 min, cooled to room temperature, and concentrated. Column chromatography on silica of the residue (gradient 25- 30% ethyl acetate in hexane) afforded 1,1-dimethyl 7-(l-{[(l,l-dimethylethyl)oxy]carbonyl}-2- methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepine-4(5H)-carboxylate (13.2 g, 76% yield) as an amorphous solid. MS (EI) for C 27 H 33 N 3 O 5 : 480(MH + ). [00126] STEP 4: A solution of 1 , 1 -dimethyl 7-(l-{[(l,l-dimethylethyl)oxy]carbonyl}-2- methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepine-4(5H)-carboxylate (13.1 g, 27 mmol) in a mixture of methanol (20 mL) and 4 N hydrogen chloride in dioxane (30 mL) was refluxed for 15 min. After cooling to room temperature ethyl ether (100 mL) was added, and the reaction mixture was concentrated. Another portion of ethyl ether (100 mL) was added, the precipitate was filtered off, washed several times with ethyl ether, and dried to give 7-(2-methyl- lH-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine dihydrochloride (8.9 g, 93% yield) as a light beige solid. 1 HNMR (400 MHz, CD 3 OD): 7.93(s, IH), 7.86-7.67(m, 4H), 7.28(s, IH), 4.54(s, 2H), 4.33-4.23(m, 2H), 3.65-3.54(m, 2H), 2.91(s, 3H); MS (EI) for C n H 17 N 3 O: 280 (MH + ). [00127] STEP 5: 7-(2-methyl-lH-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine dihydrochloride (6.95 g, 19.73 mmol) was suspended in dichloromethane (10OmL) and cooled to 0 0 C. To the resulting mixture was added DIPEA (19 mL, 109 mmol) followed by allyl chloroformate (4.6 mL, 43.4 mmol) and stirring was continued at 0 0 C for 30 minutes then warmed to room temperature. The reaction mixture was then charged with additional DIPEA (3.4 mL) and allyl chloroformate (1 mL) then stirred an additional 30 minutes at room temperature. The resulting solution was then concentrated and the residue azeotroped once from methanol (100 mL). The residue was then taken back into methanol (100 mL) followed by portionwise addition of 2 M aqueous sodium hydroxide (20 mL) and the mixture was allowed to stir for 1 h at room temperature. The solution was then concentrated and the residue partitioned with chloroform and dilute brine. The organic phase was then dried over anhydrous sodium sulfate, filtered and concentrated to give prop-2-en-l-yl 7-(2-methyl-lH-benzimidazol-6-yl)-2,3- dihydro- 1 ,4-benzoxazepine-4(5H)-carboxylate as an amorphous residue which was carried forward directly into step 6. [00128] STEP 6: prop-2-en-l-yl 7-(2-methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4- benzoxazepine-4(5H)-carboxylate as obtained in step 5 was taken into TΗF (100 mL) followed by addition of pyridine (2.5 mL, 30 mml) and di-tert-butyl dicarbonate (4.9 g, 22.4 mmol) and the mixture was allowed to stir at room temperature over 12 h. The resulting solution was concentrated and the residue partitioned with ethyl acetate and 10% aqueous citric acid. The organic phase was washed twice with additional 10% aqueous citric acid then brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography using 3:2 to 4:1 ethyl acetate in hexanes as eluent to afford 7-[l-[(l,l- dimethylethoxy)carbonyl]-2-methyl-lH-benzimidazol-6-yl]-2,3-dihydro-l,4-benzoxazepine- 4(5H)-carboxylic acid 2-propenyl ester (10.2 g) as a pale yellow amorphous residue. MS (EI) for C 26 H 29 N 3 O 5 : 465 (MH + ). [00129] STEP 7: 7-[l-[(l,l-dimethylethoxy)carbonyl]-2-methyl-lH-benzimidazol-6-yl]-2,3- dihydro- 1 ,4-benzoxazepine-4(5H)-carboxylic acid 2-propenyl ester (110 mg, 0.27 mmol) was taken into TΗF (1 mL) followed by addition of sodium triacetoxyborohydride (254 mg, 1.2 mmol) then tetrakis(triphenylphosphine)palladium (0) (6.1 mg, 0.005 mmol) and the mixture was stirred for 1 h at room temperature. The mixture was diluted with chloroform and partitioned with dilute aqueous sodium bicarbonate. The aqueous phase was extracted twice with chloroform and the combined organic layers were dried over anhydrous sodium sulfate then filtered and concentrated to give crude 1,1-dimethylethyl 2-methyl-6-(2,3,4,5-tetrahydro-l,4- benzoxazepin-7-yl)-lH-benzimidazole-l-carboxylate (109.5 mg) as an amorphous residue. MS (EI) for C 22 H 25 N 3 O 3 : 380 (MH + ). [00130] STEP 8: Phosgene (20 W% in toluene) (190 uL, 0.38 mmol) was added by syringe to a 0 0 C cooled solution of pyridine (100 uL, 1.2 mmol) in chloroform (3 mL) followed by addition of 1 , 1 -dimethylethyl 2-methyl-6-(2,3,4,5-tetrahydro-l,4-benzoxazepin-7-yl)-lH- benzimidazole-1-carboxylate as obtained in step 7 as a solution in chloroform (1 mL). The mixture was stirred for 15 minutes at 0 0 C then partitioned with 10% aqueous citric acid. The organic phase was dried over anhydrous sodium sulfate then filtered and concentrated. The residue was purified by silica gel chromatography to give 1,1-dimethylethyl 6- [4- (chlorocarbonyl)-2,3 ,4,5-tetrahydro- 1 ,4-benzoxazepin-7-yl]- lH-benzimidazole- 1 -carboxylate (62.6 mg, 59% yield) as a yellow amorphous residue. MS (EI) for C 23 H 24 ClN 3 O 4 : 442 (MH + ). [00131] STEP 9: 1,1-dimethylethyl 6-[4-(chlorocarbonyl)-2,3,4,5-tetrahydro-l,4- benzoxazepin-7-yl]-lH-benzimidazole-l -carboxylate (40 mg, 0.09 mmol), 2-(4- chlorophenyl)piperidine (reagent preparation 1) and DIPEA (78 uL, 0.45 mmol) in TΗF (2 mL) was heated at 60 0 C over 12 h. The resulting solution was concentrated and the residue purified by silica gel chromatography using 20-50% ethyl acetate in hexanes as eluent to provide . , 1 -dimethylethyl 6-(4- { [2-(4-chlorophenyl)piperidin- 1 -yljcarbonyl} -2,3 ,4,5 -tetrahydro- 1,4- benzoxazepin-7-yl)-2-methyl-lH-benzimidazole-l -carboxylate (38 mg, 70% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl 3 ): 8.14 (d, 0.4H), 7.94 (dd, 0.6H), 7.82 (d, 0.6H), 7.70 (dd, 0.4H), 7.57 -7.50 (m, 3H), 7.16 (dd, IH), 4.79 (s, IH), 4.71 (br s, IH), 4.20-4.13 (m, 3H), 4.03 (m, IH), 2.86 (s, 3H), 1.73 (s, 9H). [00132] STEP 10: 1,1-dimethylethyl 6-(4-{ [2-(4-chlorophenyl)piperidin- l-yl]carbonyl}- 2,3,4,5-tetrahydro-l,4-benzoxazepin-7-yl)-2-methyl-lH-benzimidazole-l-carboxylate as obtained in step 9 was taken into methanol (1 mL) followed by addition of 4 N hydrogen chloride in dioxane solution (1 mL) and the resulting solution was allow to stir for 2 h at room temperature. The solution was then concentrated and the residue purified by preparative reverse phase ΗPLC to give 4-{[2-(4-chlorophenyl)piperidin-l-yl]carbonyl}-7-(2-methyl-lH- benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine (17 mg, 55 % yield) as a colorless solid. 1 H NMR (400 MHz, de-DMSO): 7.68 (s, 0.5H), 7.54-7.43 (m, 3.5H), 7.30-7.21 (m, 5H), 7.02 (d, IH), 4.59-4.48 (m, 4H), 4.21-4.09 (m, 3H), 3.64 (s, 3H), 3.05 (m, IH), 1.94 (m, IH), 1.78 (m, IH), 1.63-1.43 (br m, 5H). MS (EI) for C 29 H 29 ClN 4 O 2 : 502 (MH + ). [00133] Using analogous synthetic techniques and substituting with alternative starting reagents in step 9 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated. [00134] 7-(2-methyl-lH-benzimidazol-6-yl)-4-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,5- tetrahydro- 1,4-benzoxazepine. Synthesized according to the method of example 1 using 4- methylpiperidine in step 9. MS (EI) for C 24 H 28 N 4 O 2 : 406 (MH + ). [00135] 7-(2-methyl-lH-benzimidazol-6-yl)-4-[(2-methylpiperidin-l-yl)carbonyl]-2,3,4,5- tetrahydro- 1,4-benzoxazepine. Prepared according to the method of example 1 by using racemic 2-methylpiperidine in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.64 (s, IH), 7.52 (d, 2H), 7.47 (dd, IH), 7.42 (dd, IH), 7.04 (d, IH), 4.48 (m, 2H), 4.20 (m, 2H), 3.95 (m, IH), 3.67 (m, 2H), 3.35 (m, IH), 3.12 (m, IH), 2.58 (s, 3H), 1.79-49 (m, 6H), 1.19 (d, 3H); MS (EI) for C 24 H 28 N 4 O 2 : 405 (MH + ). [00136] 7-(2-methyl-lH-benzimidazol-6-yl)-4-{[4-(trifluoromethyl)piperidin-l-yl]carbonyl}- 2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4-(trifluoromethyl)piperidine in step 9. 1 H NMR (400 MHz, methanol-dt): 7.66 (s, IH), 7.53 (m, 2H), 7.47 (m, 2H), 7.04 (d, IH), 4.51 (s, 2H), 4.21 (m, 2H), 3.77 (m, 2H), 3.70 (m, 2H), 2.87 (m, 2H), 2.61 (s, 3H), 2.39 (m, IH), 1.86 (m, 2H), 1.58 (m, 2H); MS (EI) for C 24 H 25 F 3 N 4 O 2 : 459 (MH + ). [00137] 4-[(4-fluoropiperidin-l-yl)carbonyl]-7-(2-methyl-lH-benzimidazol-6-yl)-2,3,4,5- tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4- fiuoropiperidine in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.64 (s, IH), 7.53 (d, IH), 7.51 (s, IH), 7.47 (dd, IH), 7.43 (dd, 1H),7.O4 (d, IH) 4.52 (s, 2H), 4.21 (m, 2H), 3.70 (m, 2H), 3.41 (m, 2H), 3.24 (m, 2H), 2.58 (s, 3H), 1.93 (m, 3H), 1.81 (m, 2H); MS (EI) for C 23 H 25 FN 4 O 2 : 409 (MH + ). [00138] l-{[7-(2-methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin-4(5H)- yl]carbonyl}piperidine-4-carbonitrile. Prepared according to the method of example 1 by using piperidine-4-carbonitrile in step 9. 1 H NMR (400 MHz, methanol^): 7.67 (s, IH), 7.55 (d, IH), 7.52 (d, IH), 7.47 (m, 2H), 7.04 (d, IH), 4.52 (s, 2H), 4.21 (m, 2H), 3.70 (m, 2H), 3.47 (m, 2H), 3.15 (m, 2H), 2.99 (m, IH), 2.61 (s, 3H), 1.97 (m, 2H), 1.83 (m, 2H); MS (EI) for C 24 H 25 N 5 O 2 : 416 (MH + ). [00139] 3-(l-{[7-(2-methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin-4(5H)- yl]carbonyl}piperidin-4-yl)propan-l-ol. Prepared according to the method of example 1 by using 3-(piperidin-4-yl)propan-l-ol in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.65 (s, IH), 7.52 (m, 2H), 7.47 (dd, IH), 7.43 (dd, IH), 7.04 (d, IH), 4.49 (s, 2H), 4.20 (m, 2H), 3.69 (m, 4H), 3.54 (t, 2H), 2.82 (t, 2H), 2.58 (s, 3H), 1.73 (m, 2H), 1.56 (m, 2H), 1.47 (m, IH), 1.34 (m, 2H), 1.23 (m, 2H); MS (EI) for C 26 H 32 N 4 O 3 : 449 (MH + ). [00140] 4-[(4-ethylpiperidin-l-yl)carbonyl]-7-(2-methyl-lH-benzimidazol-6-yl)-2,3,4,5- tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4- ethylpiperidine in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.64 (s, IH), 7.52 (m, 2H), 7.47 (dd, IH), 7.43 (d, IH), 7.04 (d, IH), 4.49 (s, 2H), 4.20 (m, 2H), 3.69 (m, 4H), 2.82 (m, 2H), 2.59 (s, 3H), 1.72 (m, 21H), 1.32 (m, 3H), 1.20 (m, 2H), 0.92 (t, 3H); MS (EI) for C 25 H 30 N 4 O 2 : 419 (MH + ). [00141] (±)-4-{[(25,45)-2,4-dimethylpiperidin-l-yl]carbonyl}-7-(2-methyl-lH-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using racemic 2,4-dimethylpiperidine in step 9 and purification of the title compound by preparatory reverse phase HPLC (Phenomenex Luna 150x3 Omm, 0.1% aqueous ammonium acetate-acetonitrile 20-90%, 15min, retention time 8.7 min). 1 H NMR (400 MHz, methanol-d 4 ): 7.68 (s, IH), 7.56 (d, IH), 7.52-7.46 (m, 3H), 7.05 (d, IH), 4.46 (m, 2H), 4.21 (m, 2H), 4.07 (m, IH), 3.65 (m, 2H), 3.47 (m, IH), 3.12 (m, IH), 2.63 (s, 3H), 1.85 (m, IH), 1.64 (m, IH), 1.45 (m, IH), 1.37 (m, IH), 1.21 (d, 3H), 1.16 (m, IH), 0.93 (d, 3H); MS (EI) for C 25 H 30 N 4 O 2 : 419 (MH + ). [00142] (±)-4- { [(2,S,4i?)-2,4-dimethylpiperidin- 1 -yl]carbonyl} -7-(2-methyl- lH-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using racemic 2,4-dimethylpiperidine in step 9 and purification of the title compound by preparatory reverse phase ΗPLC (Phenomenex Luna 150x30mm, 0.1% aqueous ammonium acetate-acetonitrile 20-90%, 15min, retention time 9.5 min). 1 H NMR (400 MHz, methanol-d 4 ): 7.66 (m, IH), 7.53 (m, 2H), 7.47 (dd, IH), 7.44 (dd, IH), 7.05 (d, IH), 4.70 (d, IH), 4.60 (d, IH), 4.19 (m, IH), 4.11 (m, IH), 3.94 (m, IH), 3.79 (m, IH), 3.27 (m, IH), 2.96 (m, IH), 2.69 (m, IH), 2.59 (s, 3H), 1.65 (m, 2H)1.51 (m, IH), 1.27 (m, IH), 1.02 (m, IH), 0.95 (t, 3H), 0.94 (t, 3H); MS (EI) for C 25 H 30 N 4 O 2 : 419 (MH + ) [00143] 7-(2-methyl-lH-benzimidazol-6-yl)-4-{[4-(methylthio)piperidin-l-yl]carbonyl}- 2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4-(methylthio)piperidine (synthesized according to reagent preparation 7) in step 9. 1 H NMR (400 MHz, DMSO-de): 7.66 (m, IH), 7.54 (m, 2H), 7.48 (m, IH), 7.40 (m, IH), 7.01 (m, IH), 4.44 (s, 2H), 4.18 (m, 2H), 3.59 (m, 2H), 3.51 (m, 2H), 2.80 (m, 3H), 2.54 (m, 3H), 2.05 (m, 3H), 1.92 (m, 3H), 1.45 (m, 2H); MS (EI) for C 24 H 28 N 4 O 2 S: 437 (MH + ). [00144] l-{[7-(2-methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin-4(5H)- yl]carbonyl}-4-[3-(trifluoromethyl)phenyl]piperidin-4-ol. Prepared according to the method of example 1 by using 4-(3-(trifluoromethyl)phenyl)piperidin-4-ol in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.85 (s, IH), 7.71 (d, IH), 7.64 (s, IH), 7.56-7.40 (m, 6H), 7.05 (d, IH), 4.55 (s, 2H), 4.23 (m, 2H), 3.74 (m, 2H), 3.64 (m, 2H), 3.39 (m, 2H), 2.57 (s, 3H), 2.12 (m, 2H), 1.70 (m, 2H); MS (EI) for C 30 H 29 F 3 N 4 O 3 : 551 (MH + ). [00145] 7-(2-methyl-lH-benzimidazol-6-yl)-4-{[2-(trifluoromethyl)piperidin-l-yl]carbonyl}- 2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using racemic 2-(trifluoromethyl)piperidine (synthesized according to reagent preparation 3) in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.68 (s, IH), 7.55 (m, IH), 7.49 (m, 3H), 7.05 (d, IH), 4.64 (m, IH), 4.51 (m, 2H), 4.31 (m, IH), 4.10 (m, IH), 3.70 (m, 2H), 3.60 (m, IH), 2.62 (s, 3H), 2.01 (m, IH), 1.85 (m, IH), 1.71 (m, 2H), 1.48 (m, IH); MS (EI) for C 24 H 25 N 4 O 2 : 459 (MH + ). [00146] 7-(2-methyl-lH-benzimidazol-6-yl)-4-[(4-propylpiperidin-l-yl)carbonyl]-2,3,4,5- tetrahydro-l,4-benzoxazepine. Prepared as the acetate salt according to the method of example 1 by using 4-propylpiperidine in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.63 (m, IH), 7.53- 7.39 (m, 4H), 7.02 (d, IH), 4.46 (s, 2H), 4.18 (m, 2H), 3.66 (m, 4H), 2.79 (m, 2H), 2.58 (s, 3H), 1.98 (s, 3H), 1.68 (m, 2H), 1.44 (m, IH), 1.33 (m, 2H), 1.28-1.12 (m, 4H), 0.89 (t, 3H); MS (EI) for C 26 H 32 N 4 O 2 : 433 (MH + ). [00147] 4-(2-azabicyclo[2.2.2]oct-2-ylcarbonyl)-7-(2-methyl-lH-benzimidazol-6-yl)-2,3,4,5- tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 2- azabicyclo[2.2.2]octane in step 9. 1 H NMR (400 MHz, DMSO-d 6 ): 12.30 (br. s, IH), 7.62 (br. s, IH), 7.53 (d, IH), 7.50 (m, IH), 7.46 (dd, IH), 7.36 (dd, IH), 7.00 (d, IH), 4.42 (s, 2H), 4.18 (m, 2H), 3.56 (m, 2H), 1.91 (s, 3H), 1.89 (m, IH), 1.81 (m, IH), 1.57 (m, 6H); MS (EI) for C 25 H 28 N 4 O 2 : 417 (MH + ). [00148] 4-[(4,4-dimethylpiperidin-l-yl)carbonyl]-7-(2-methyl-lH-benzimidazol-6-yl)-2,3,4,5- tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4,4- dimethylpiperidine in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.64 (s, IH), 7.52 (m, 2H), 7.47 (dd, IH), 7.43 (dd, IH), 7.04 (d, IH), 4.49 (s, 2H), 4.20 (m, 2H), 3.67 (m, 2H), 3.27 (m, 4H), 2.58 (s, 3H), 1.41 (m, 4H), 0.99 (s, 6H); MS (EI) for C 25 H 30 N 4 O 2 : 419 (MH + ). [00149] 4-(8-azabicyclo[3.2.1]oct-8-ylcarbonyl)-7-(2-methyl-lH-benzimidazol-6-yl)-2,3,4,5- tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 using 8- azabicyclo[3.2.1]octane step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.63 (s, IH), 7.53-7.39 (m, 4H), 7.03 (d, IH), 4.59 (s, 2H), 4.21 (t, 2H), 4.06 (br s, 2H), 3.75 (t, 2H), 2.57 (s, 3H), 1.92-1.49 (m, 10H); MS (EI) for C 25 H 28 N 4 O 2 : 417 (MH + ). [00150] 4- {[4-(difluoromethyl)piperidin-l-yl]carbonyl}-7-(2 -methyl- lH-benzimidazol-6-yl)- 2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4-(difluoromethyl)piperidine (synthesized according to reagent preparation 4) in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.68 (s, IH), 7.56 (d, IH), 7.49 (m, 3H), 7.04 (d, IH), 4.51(s, 2H), 4.20 (m, 2H), 3.75 (m, 2H), 3.70 (m, 2H), 2.84 (m, 2H), 2.63 (s, 3H), 1.99 ( (m, 2H), 1.75 (m, 2H), 1.47 (m, 2H); MS (EI) for C 24 H 26 F 2 N 4 O 2 : 441 (MH + ). [00151] N-methyl-7-(2-methyl- lH-benzimidazol-6-yl)-N-[(15)- 1 -phenylethyl]-2,3-dihydro- l,4-benzoxazepine-4(5H)-carboxamide. Prepared according to the method of example 1 by using (,S)-N-methyl-l-phenylethanamine in step 9. 1 H ΝMR (400 MHz, methanol-d 4 ): 7.50 (d, IH), 7.41 (d, IH), 7.37 (dd, IH), 7.26 (dd, IH), 7.23 (d, IH), 7.18 (m, 2H), 7.11 (m, 3H), 6.96 (d, IH), 5.01 (q, IH), 4.41 (m, 2H), 4.15 (m, 2H), 3.61 (m, 2H), 2.55 (s, 3H), 2.49 (s, 3H), 1.44 (d, 3H); MS (EI) for C 27 H 28 N 4 O 2 : 441 (MH + ). [00152] 4- {[4-(fluoromethyl)piperidin-l-yl]carbonyl}-7-(2 -methyl- lH-benzimidazol-6-yl)- 2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4-(fiuoromethyl)piperidine (synthesized according to reagent preparation 5) in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.71 (s, IH), 7.60 (d, IH), 7.55 (dd, IH), 7.52 (d, IH), 7.48 (dd, IH), 7.05 (d, IH), 4.50 (s, 2H), 4.35 (d, IH), 4.23 (d, IH), 4.20 (m, 2H), 3.72 (m, 4H), 2.85 (m, 2H), 2.68 (s, 3H), 1.88 (m, IH), 1.72 (m, 2H), 1.36 (m, 2H); MS (EI) for C 24 H 27 FN 4 O 2 : 423 (MH + ). [00153] 4- { [4-( 1 , 1 -difluoroethyl)piperidin- 1 -yl] carbonyl} -7-(2 -methyl- lH-benzimidazol-6- yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4-(l,l-difluoroethyl)piperidine (synthesized according to reagent preparation 6) in step 9. 1 H NMR (400 MHz, methanol-d 4 ): 7.67 (s, IH), 7.53 (m, 2H), 7.47 (m, 2H), 7.04 (d, IH), 4.50 (s, 2H), 4.21 (m, 2H), 3.77 (m, 2H), 3.69 (m, 2H), 2.83 (m, 2H), 2.61 (s, 3H), 1.80 (m, 2H), 1.55 (t, 3H), 1.48 (m, 2H); MS (EI) for C 25 H 28 F 2 N 4 O 2 : 455 (MH + ). [00154] 7-(2-methyl- 1 H-benzimidazol-6-yl)-4- { [4-( 1 -methylethyl)piperidin- 1 -yl]carbonyl} - 2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 4-isopropylpiperidine in step 9. 1 H NMR (400 MHz, DMSO-d 6 ): 12.23 (br. s, IH), 7.72-7.42 (m, 4H), 7.35 (m, IH), 7.01 (d, IH), 4.42 (s, 2H), 4.17 (m, 2H), 3.59 (m, 4H), 2.67 (m, 2H), 1.66 (m, 2H), 1.42 (m, IH), 1.17 (m, 3H), 0.85 (d, 6H); MS (EI) for C 26 H 32 N 4 O 2 : 433 (MH + ). [00155] 8-{[7-(2-Methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin-4(5H)- yl]carbonyl}-3-(trifluoromethyl)-8-azabicyclo[3.2.1]octan-3-(endo)-ol. Prepared according to the method of example 1 by using 3-(trifluoromethyl)-8-azabicyclo[3.2.1]octan-3-(endo)-ol hydrochloride (reagent preparation 8) in step 9. (400 MHz, methanol-d 4 ): 7.63 (br, IH), 7.50 (d, IH), 7.47 to 7.44 (m, 2H), 7.41 (dd, IH), 7.03 (d, IH), 4.57 (s, 2H), 4.21 (m, 2H), 4.15 (br, 2H), 3.75 (m, 2H), 2.21 (s, 3H), 2.21 to 2.11 (m, 4H), 1.91 to 1.86 (m, 2H), 1.78 (d, 2H); MS (EI) for C 26 H 27 F 3 N 4 O 3 : 501 (MH + ). [00156] 3-Methyl-8-{[7-(2-methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin- 4(5H)-yl]carbonyl}-8-azabicyclo[3.2.1]octan-3-(endo)-ol. Prepared according to the method of example 1 by using 3-methyl-8-azabicyclo[3.2.1]octan-3-(endo)-ol hydrochloride (reagent preparation 9) in step 9. (400 MHz, methanol-d 4 ): 7.54 (d, IH), 7.41 (m, IH), 7.38 (m, IH), 7.35 (d, IH), 7.32 (dd, IH), 6.93 (d, IH), 4.47 (s, 2H), 4.11 (m, 2H), 3.96 (m, 2H), 3.64 (m, 2H), 2.48 (s, 3H), 2.07 (q, 2H), 2.07 (dd, 2H), 1.73 to 1.68 (m, 2H), 1.65 (d, 2H), 1.06 (s, 3H); MS (EI) for C 26 H 30 N 4 O 3 : 447 (MH + ). [00157] 4-[(3-Fluoro-3-(CTύfo)-methyl-8-azabicyclo[3.2.1]oct-8-yl)carbonyl]-7-(2-methyl-lH- benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 3-fluoro-3-(endo)-methyl-8-azabicyclo[3.2.1]octane hydrochloride (reagent preparation 10) in step 9. (400 MHz, methanol-d 4 ): 7.64 (br, IH), 7.53 to 7.49 (m, 2H), 7.48 (dd, 2H), 7.43 (dd, IH), 7.04 (d, IH), 4.61 (s, 2H), 4.22 (m, 2H), 4.13 (br, 2H), 3.77 (m, 2H), 2.57 (s, 3H), 2.40 (dd, IH), 2.30 (dd, IH), 1.96 to 1.87 (m, 4H), 1.77 to 1.70 (m, 2H), 1.56 to 1.49 (d, 3H); MS (EI) for C 26 H 29 FN 4 O 2 : 449 (MH + ). [00158] (±)-[(2R,4 1 S)-l-{[7-(2-methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin- 4(5H)-yl]carbonyl}-2-phenylpiperidin-4-yl]methanol. Prepared according to the method of example 1 by using (±)-(2i?,4S)-2-phenylpiperidin-4-yl)methanol (reagent preparation 2) in step 9. 1 H NMR (400 MHz, d 6 -DMSO): 12.20 (br s, IH), 7.65 (s, IH), 7.55 (d, IH), 7.50 (m, IH), 7.47 (d, IH), 7.43 (dd, IH), 7.33 (m, IH), 7.11 (dd, 2H), 7.07-7.00 (m, 3H), 5.18 (t, IH), 4.48 (s, 2H), 4.08 (m, 2H), 3.98 (m, 2H), 3.84 (m, 2H), 3.70 (m, 2H), 2.51 (s, 3H), 1.84 (m, 2H), 1.71 (m, IH), 1.58 (m, 2H). MS (EI) C 30 H 32 N 4 O 3 : 497 (MH + ). [00159] 7-(2-methyl-lH-benzimidazol-6-yl)-4-[(l-phenyl-3,4-dihydroisoquinolin-2(lH)- yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepine. Prepared according to the method of example 1 by using 1 -phenyl- 1,2, 3, 4-tetrahydroisoquino line in step 9. 1 H NMR (400 MHz, d 3 -Me0H): 7.58 (d, IH), 7.49 (m, 2H), 7.32 (dd, IH), 7.24 (s, IH), 7.21 (m, 3H), 7.12 (m, 3H), 7.06 (d, IH), 7.01 (m, 3H), 6.82 (d, IH), 6.03 (s, IH), 4.54 (dd, 2H), 4.25 (m, 2H), 3.70 (m, 3H), 3.30 (m, IH), 3.00 (m, IH), 2.85 (2m, IH), 2.59 (s, 3H). MS (EI) C 33 H 30 N 4 O 2 : 515 (MH + ). [00160] 4-{[3-(en 1 - { [7-(2-methyl- lH-benzimidazol-6-yl)-2,3 -dihydro- 1,4- benzoxazepin-4(5H)-yl]carbonyl}piperidin-4-ol. Prepared as the free base as described in example 2 using methyl chloro formate in step 2 and 4-(4-chlorophenyl)piperidin-4-ol in step 5. 1 H NMR (400 MHz, d 6 -DMSO): 12.24 (br s, IH), 7.77-7.33 (m, 9H), 7.02 (d, IH), 5.16 (s, IH), 4.48 (s, 2H), 4.19 (br s, 2H), 3.62 (br s, 2H), 3.46 (d, 2H), 3.17 (t, 2H), 2.50 (s, 3H), 1.93 (m, 2H), 1.55 (d, 2H); MS (EI) for C 29 H 29 ClN 4 O 3 : 518 (MH + ). [00185] 4-(4-bromophenyl)-l-{[7-(2-methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4- benzoxazepin-4(5H)-yl]carbonyl}piperidin-4-ol. Prepared as described in example 2 using 4-(4- bromophenyl)piperidin-4-ol in step 5. 1 H NMR (400 MHz, methanol-d 4 ): 7.64 (s, IH), 7.55- 7.35 (m, 8H), 7.05 (d, IH), 4.53 (s, 2H), 4.22 (t, 2H), 3.72 (t, 2H), 3.60 (d, 2H), 3.32 (m, 2H), 2.60 (s, 3H), 2.04 (m, 2H), 1.67 (d, 2H); MS (EI) for C 29 H 29 BrN 4 O 3 : 562 (MH + ). [00186] 8-{[7-(2-methyl-lH-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin-4(5H)- yl]carbonyl} -3-[3-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1 ]octan-3-(enS6 (S240/244) ELISA Assay [00264] MCF-7 cells (ATCC) or PC-3 cells were seeded at 24000 cells per well in 96-well plates (Corning, 3904) in DMEM (Cellgro) containing 10% FBS (Cellgro), 1% NEAA (Cellgro) and 1% penicillin-streptomycin (Cellgro). Cells were incubated at 37°C, 5% CO2 for 48 h, and the growth medium was replaced with serum-free DMEM or in medium containing 0.4% BSA. Serial dilutions of the test compound in 0.3% DMSO (vehicle) were added to the cells and incubated for 3h. To fix the cells, medium was removed and lOOμL/well of 4% formaldehyde (Sigma Aldrich, F8775) in TBS (20 mM Tris, 500 mM NaCl) was added to each well at RT for 30 min. Cells were washed 4 times with 200μL TBS containing 0.1% Triton X-100 (Sigma, catalog # T9284). Plates were blocked with lOOμL Odyssey blocking buffer (Li-Cor Biosciences, 927-40000) for Ih at RT. Anti-pS6 (S240/244) antibody (Cell Signaling Technology, 2215) and anti-total-S6 antibody (R&D systems, MAB5436) were diluted 1 :400 in Odyssey blocking buffer, and 50μL of the antibody solution containing both antibodies was added to one plate to detect pS6 and total S6. After incubation overnight at 4°C, plates were washed 4 times with 200μL TBS containing 0.1% Tween20 (Bio-Rad, catalog # 170-6351) (TBST). Goat anti-rabbit and Goat anti-mouse secondary antibody (Li-Cor Biosciences, catalog # 926-32221 and 926- 32210) conjugated to IRDye were diluted 1 :400 in Odyssey blocking buffer containing 0.1% Tween20. 50μL of antibody solution containing both antibodies was added to each well and incubated for Ih at RT. Plates were washed 3 times with 200μL TBST and 2 times with 200μL TBS. Fluorescence was read on an Odyssey plate reader. IC50 values were determined based on the ratio of pS6 to total S6 signal for compound treated wells, normalized to the DMSO-treated control wells. [00265] In one embodiment, the Compound of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 0.5 μM or less. In another embodiment, the Compound of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 0.25 μM or less, the Compound of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 0.2 μM or less, the Compound of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 0.1 μM or less. [00266] In one embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of 2.0 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of 1.0 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of 0.5 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of 0.25 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of 0.2 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of 0.1 μM or less. Biological Example 5-11 Pharmacodynamic xenograft tumor models [00267] Female and male athymic nude mice (NCr) 5-8 weeks of age and weighing approximately 20-25 g are used in the following models. Prior to initiation of a study, the animals are allowed to acclimate for a minimum of 48 h. During these studies, animals are provided food and water ad libitum and housed in a room conditioned at 70-75 0 F and 60% relative humidity. A 12 h light and 12 h dark cycle is maintained with automatic timers. All animals are examined daily for compound-induced or tumor-related deaths. MCF-7 Breast adenocarcinoma model [00268] MCF7 human mammary adenocarcinoma cells are cultured in vitro in DMEM (Cellgro) supplemented with 10% Fetal Bovine Serum (Cellgro), Penicillin-Streptomycin and non-essential amino acids at 37 0 C in a humidified 5% CO 2 atmosphere. On day 0, cells are harvested by trypsinization, and 5 x 10 6 cells in 100 μL of a solution made of 50% cold Hanks balanced salt solution with 50% growth factor reduced matrigel (Becton Dickinson) implanted subcutaneously into the hindflank of female nude mice. A transponder is implanted into each mouse for identification and data tracking, and animals are monitored daily for clinical symptoms and survival. [00269] Tumors are established in female athymic nude mice and staged when the average tumor weight reached 100-200 mg. A Compound of the Invention is orally administered as a solution/fine suspension in water (with 1 : 1 molar ratio of 1 N HCL) once-daily (qd) or twice-daily (bid) at 10, 25, 50 and 100 mg/kg for 14 days. During the dosing period of 14-19 days, tumor weights are determined twice-weekly and body weights are recorded daily. Colo-205 colon model [00270] Colo-205 human colorectal carcinoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37 0 C in a humidified, 5% CO 2 atmosphere. On day 0, cells are harvested by trypsinization, and 3xlO 6 cells (passage 10-15, >95% viability) in 0.1 mL ice-cold Hank's balanced salt solution are implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. [00271] Tumors are established in female athymic nude mice and staged when the average tumor weight reached 100-200 mg. A Compound of the Invention is orally administered as a solution/fine suspension in water (with 1 : 1 molar ratio of 1 N HCL) once-daily (qd) or twice-daily (bid) at 10, 25, 50 and 100 mg/kg for 14 days. During the dosing period of 14 days, tumor weights are determined twice-weekly and body weights are recorded daily. PC-3 prostate adenocarcinoma model [00272] PC-3 human prostate adenocarcinoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 20% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37 0 C in a humidified 5% CO 2 atmosphere. On day 0, cells are harvested by trypsinization and 3xlO 6 cells (passage 10-14, >95% viability) in 0.1 mL of ice-cold Hank's balanced salt solution are implanted subcutaneously into the hindflank of 5-8 week old male nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. [00273] Tumors are established in male athymic nude mice and staged when the average tumor weight reached 100-200 mg. A Compound of the Invention is orally administered as a solution/fine suspension in water (with 1 : 1 molar ratio of 1 N HCl) once-daily (qd) or twice-daily (bid) at 10, 25, 50, or 100-mg/kg for 19 days. During the dosing period of 14-19 days, tumor weights are determined twice-weekly and body weights are recorded daily. U-87 MG human glioblastoma model [00274] U-87 MG human glioblastoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and nonessential amino acids at 37 0 C in a humidified 5% CO 2 atmosphere. On day 0, cells are harvested by trypsinization and 2xlO 6 cells (passage 5, 96% viability) in 0.1 mL of ice-cold Hank's balanced salt solution are implanted intradermally into the hindflank of 5-8 week old female nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. Body weights are recorded daily. A549 human lung carcinoma model [00275] A549 human lung carcinoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and nonessential amino acids at 37 0 C in a humidified 5% CO 2 atmosphere. On day 0, cells are harvested by trypsinization and 1OxIO 6 cells (passage 12, 99% viability) in 0.1 mL of ice-cold Hank's balanced salt solution are implanted intradermally into the hindflank of 5-8 week old female nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. Body weights are recorded daily. A2058 human melanoma model [00276] A2058 human melanoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and nonessential amino acids at 37 0 C in a humidified, 5% CO2 atmosphere. On day 0, cells are harvested by trypsinization and 3xlO 6 cells (passage 3, 95% viability) in 0.1 mL ice-cold Hank's balanced salt solution are implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. Body weights are recorded daily. WM-266-4 human melanoma model [00277] WM-266-4 human melanoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and nonessential amino acids at 37 0 C in a humidified, 5% CO 2 atmosphere. On day 0, cells are harvested by trypsinization and 3xlO 6 cells (passage 5, 99% viability) in 0.1 mL ice-cold Hank's balanced salt solution are implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. Body weights are recorded daily. [00278] Tumor weight (TW) in the above models is determined by measuring perpendicular diameters with a caliper, using the following formula: tumor weight (mg) = [tumor volume = length (mm) x width 2 (mm 2 )]/2 These data were recorded and plotted on a tumor weight vs. days post-implantation line graph and presented graphically as an indication of tumor growth rates. Percent inhibition of tumor growth (TGI) is determined with the following formula: where Xo = average TW of all tumors on group day X f = TW of treated group on Day f Y f = TW of vehicle control group on Day f If tumors regress below their starting sizes, then the percent tumor regression is determined with the following formula: Tumor size is calculated individually for each tumor to obtain a mean ± SEM value for each experimental group. Statistical significance is determined using the 2-tailed Student's t-test (significance defined as P<0.05). [00279] The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has been described with reference to various specific embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled. All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.","lang":"en","source":"WIPO_FULLTEXT","data_format":"ORIGINAL"}},"description_lang":["en"],"has_description":true,"has_docdb":true,"has_inpadoc":true,"has_full_text":true,"biblio_lang":"en"},"jurisdiction":"WO","collections":[],"usersTags":[],"lensId":"019-041-955-500-923","publicationKey":"WO_2010_138490_A1","displayKey":"WO 2010/138490 A1","docAssets":{"lensId":"019-041-955-500-923","pdfUrl":"https://www.lens.org/images/patent/WO/2010138490/A1/WO_2010_138490_A1.pdf","images":[{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000001.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000001.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000002.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000002.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000003.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000003.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000004.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000004.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000005.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000005.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000006.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000006.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000007.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000007.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000008.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000008.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000009.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000009.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000010.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000010.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000011.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000011.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000012.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000012.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000013.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000013.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000014.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000014.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000015.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000015.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000016.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000016.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000017.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000017.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000018.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000018.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000019.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000019.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000020.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000020.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000021.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000021.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000022.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000022.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000023.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000023.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000024.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000024.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000025.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000025.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000026.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000026.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000027.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000027.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000028.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000028.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000029.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000029.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000030.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000030.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000031.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000031.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000032.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000032.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000033.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000033.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000034.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000034.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000035.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000035.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000036.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000036.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000037.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000037.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000038.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000038.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000039.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000039.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000040.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000040.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000041.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000041.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000042.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000042.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000043.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000043.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000044.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000044.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000045.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000045.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000046.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000046.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000047.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000047.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000048.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000048.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000049.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000049.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000050.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000050.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000051.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000051.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000052.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000052.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000053.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000053.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000054.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000054.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000055.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000055.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000056.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000056.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000057.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000057.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000058.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000058.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000059.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000059.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000060.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000060.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000061.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000061.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000062.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000062.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000063.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000063.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000064.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000064.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000065.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000065.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000066.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000066.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000067.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000067.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000068.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000068.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000069.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000069.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000070.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000070.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000071.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000071.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000072.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000072.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000073.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000073.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000074.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000074.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000075.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000075.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000076.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000076.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000077.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000077.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000078.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000078.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000079.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000079.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000080.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000080.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000081.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000081.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000082.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000082.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000083.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000083.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000084.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000084.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000085.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000085.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/10pc/00000086.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/WO/A1/2010138/2010138490/image/page/full/00000086.png"}],"fallover":false},"countryName":"WIPO (P.C.T.)","inventorModel":{"inventors":[{"name":{"value":"AAY NAING","valueNormalised":"Aay Naing"},"inventorship":null},{"name":{"value":"BLAZEY CHARLES M","valueNormalised":"Blazey Charles M"},"inventorship":null},{"name":{"value":"BOWLES OWEN JOSEPH","valueNormalised":"Bowles Owen Joseph"},"inventorship":null},{"name":{"value":"BUSSENIUS JOERG","valueNormalised":"Bussenius Joerg"},"inventorship":null},{"name":{"value":"CURTIS JEFFRY KIMO","valueNormalised":"Curtis Jeffry Kimo"},"inventorship":null},{"name":{"value":"DEFINA STEVEN CHARLES","valueNormalised":"Defina Steven Charles"},"inventorship":null},{"name":{"value":"DUBENKO LARISA","valueNormalised":"Dubenko Larisa"},"inventorship":null},{"name":{"value":"HARRIS JASON R","valueNormalised":"Harris Jason R"},"inventorship":null},{"name":{"value":"JACKSON-UGUETO EILEEN E","valueNormalised":"Jackson-ugueto Eileen E"},"inventorship":null},{"name":{"value":"KIM ANGIE INYOUNG","valueNormalised":"Kim Angie Inyoung"},"inventorship":null},{"name":{"value":"MANALO JEAN-CLAIRE LIMUN","valueNormalised":"Manalo Jean-claire Limun"},"inventorship":null},{"name":{"value":"PACK MICHAEL","valueNormalised":"Pack Michael"},"inventorship":null},{"name":{"value":"PETO CSABA J","valueNormalised":"Peto Csaba J"},"inventorship":null},{"name":{"value":"RICE KENNETH D","valueNormalised":"Rice Kenneth D"},"inventorship":null},{"name":{"value":"TSANG TSZE H","valueNormalised":"Tsang Tsze H"},"inventorship":null},{"name":{"value":"WANG LONGCHENG","valueNormalised":"Wang Longcheng"},"inventorship":null}],"inventorships":[],"unmatchedInventorships":[],"activeUserHasInventorship":false},"simpleFamilyId":156173503,"citesPatentCount":2,"countrySpec":{"countryName":"WIPO (P.C.T.)","description":"INTERNATIONAL APPLICATION PUBLISHED WITH INTERNATIONAL Search Report","rule":"","docType":"PATENT_APPLICATION"},"pageTitle":"WO 2010/138490 A1 - Benzoxazepines As Inhibitors Of Mtor And Methods Of Their Use And Manufacture","documentTitle":"Benzoxazepines As Inhibitors Of Mtor And Methods Of Their Use And Manufacture"},"claims":{"source":"xml_claims","claims":[{"lines":["What is claimed is:"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["A compound of structural formula"],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["when the combination of R1 and R2 are as defined in one of the following compounds:"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-{4-[(4-methylpipeπdin-l-yl)carboπyl]-2,3,4,5-tetrahydro-l,4-beπzoxazepin-7-yl}-Λ^-[(3Λ)-pyrrolidm-3- yl]benzamide"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["Λr-methyl-6-{4-[(4-methylpipeπdin-l-yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepm-7-yl}pyπdme-3- carboxamide"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[(4-methylpiperidm-l-yl)carbonyl]-7-(2 -methyl- 1, 3 -thiazol-5-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4- { [4-(2,3 -dimethylphenyl)piperazm- 1 -yl] carbonyl} -7-(2 -methyl- 177-benzimidazol-6-yl)-2,3 ,4,5-tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[(2-ethylpipeπdm-l-yl)carbonyl]-7-(2 -methyl- li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-({4-[2-(ethyloxy )phenyl]piperazm-l-yl}carbonyl)-7-(2 -methyl- l//-benzimidazol-6-yl)-2, 3,4, 5-tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["3-(endo)-(hydroxymethyl)-8-{[7-(2 -methyl- 177-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)- yljcarbonyl} -8-azabicyclo[3.2.1 ]octan-3-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2 -methyl- li/-benzimidazol-6-yl)-4-({4-[3-(tπfluoromethyl)phenyl]piperazin-l-yl}carbonyl)-2,3,4, 5- tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2-methyl-l//-benzimidazol-6-yl)-4-({4-[2-(methyloxy)phenyl]piperazm-l-yl}carbonyl)-2,3,4,5-tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["ΛT-ethyl-7-(2 -methyl- li/-benzimidazol-6-yl)-iV-(pyridm-4-ylmethyl)-2,3-dihydro-l,4-benzoxazepme -4(5//)- carboxamide"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["Λ?-methyl-5-(4-{[4-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4-benzoxazepm-7- yl)pyndme-2-carboxamide"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4- { [2-(2-fluorophenyl)pipeπdin-l -yl]carbonyl} -7-(2 -methyl- 177-benzimidazol-6-yl)-2,3 ,4,5-tetrahydro- 1 ,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["Λf-methyl-7-(2-methyl-l/f-benzimidazol-6-yl)-Λr-[(15)-l-phenylethyl]-2,3-dihydro-l,4-benzoxazepme-4(5i/)- carboxamide"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-(4-{[7-(2-methyl-l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}piperazin-l- yl)phenol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2-methyl-li/-benzimidazol-6-yl)-4-{[4-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2 -methyl- li/-benzimidazol-6-yl)-4-(octahydroqumohn-l(2i/)-ylcarbonyl)-2, 3, 4, 5 -tetrahydro- 1,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["Λf-[(3Λ)-pyrrolidin-3-yl]-4-(4-{[4-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepm-7-yl)benzamide"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2-methyl-li/-benzimidazol-6-yl)-4-{[2-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["(±)-(2/J,4iJ)-2-(4-fluorophenyl)- 1 - { [7-(2 -methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepin-4(5//)- yl] carbonyl } pipeπdm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["5-{4-[(4-methylpipeπdin-l-yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepm-7-yl}pyπdm-2-amme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["1 - { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -4-phenylpipeπdme- 4-carbonitnle"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4- { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5ij)-yl] carbonyl}piperazm-2-one"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[(4-fluoropiperidm-l-yl)carbonyl]-7-(2 -methyl- l//-benzimidazol-6-yl)-2, 3, 4,5-tetrahydro-l,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(l//-benzimidazol-6-yl)-4-[(4-methylpiperidin-l-yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepine"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2 -methyl- li/-benzimidazol-6-yl)-4-[(2-{4-[(tπfluoromethyl)oxy]phenyl}pipeπdm-l-yl)carbonyl]-2, 3, 4,5- tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["1 - { [7-(2-methyl- l//-benzirmdazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl}pipeπdme-4- carbonitπle"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-(7-azabicyclo[2.2.1]hept-7-ylcarbonyl)-7-(2-methyl-li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme \n\n 4-(4-bromophenyl)- 1 - {[7-(2 -methyl- 17f-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)- yl] carbonyl } pipeπdm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["(l-{[7-(2 -methyl- l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carboπyl}pipeπdm-4- yl)methanol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-[4-(l//-pyrazol-5-yl)phenyl]-4-{[4-(tnfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetraliydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["8- { [7-(2-methyl- l//-benzirmdazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -8- azabicyclo[3.2.1]octan-3-(exo)-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[(4,4-dimethylpipeπdm- 1 -yl) carbonyl] -7-(2-methyl- li/-benzimidazol-6-yl)-2, 3 ,4, 5-tetrahydro- 1 ,A- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2 -methyl- li/-benzimidazol-6-yl)-4-[(2-methylpiperidm-l-yl)carbonyl] -2,3,4, 5 -tetrahydro- 1,4 -benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2-methyl-li/-benzimidazol-6-yl)-4-[(4-methylpipendm-l-yl)carbonyl]-2,3,4,5-tetrahydro-l,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-(4-chlorophenyl)- 1 - {[7-(2 -methyl- li/-benzimidazol-6-yl)-2,3-dihydro- 1 ,4-benzoxazepm-4(5//)- yl] carbonyl } pipeπdm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-methyl-l-{[7-(2-methyl-17/-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepin-4(5//)-yl]carbonyl}pipeπdme- 4-carbonitπle"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[4-chloro-3-(tπfluoromethyl)phenyl]-l-{[7-(2-methyl-l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm- 4 (5H) -yl] c arbonyl } pipeπdm-4 -ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-(2-azabicyclo[2 2.2]oct-2-ylcarbonyl)-7-(2-methyl-li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2-methyl-li/-benzimidazol-6-yl)-4-{[4-(methylthio)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2 -methyl- li/-benzimidazol-6-yl)-4-({2-[4-(metliyloxy)phenyl]piperidm-l-yl}carbonyl)-2,3,4,5-tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["6-(4-{[4-(difluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro-l,4-benzoxazepm-7-yl)-li/- benzimidazol-2 - amine"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-( l//-benzimidazol-6-yl)-4- {[4-(tπfluoromethyl)piperidm- 1 -yl] carbonyl} -2,3 ,4, 5-tetrahydro- 1 ,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["3-(l-{[7-(2-methyl-l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}piperidm-4- yl)propan- 1 -ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["5-(4-{[4-(tπfluoromethyl)piperidin-l-yl] carbonyl} -2, 3, 4,5-tetrahydro-l,4-benzoxazepin-7-yl)pyridm-2-amme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4- { [2-(3 ,4-dichlorophenyl)pipeπdm- 1 -yl] carbonyl} -7-(2-methyl- l//-benzrmidazol-6-yl)-2, 3 ,4, 5-tetrahydro- 1 ,A- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-({2-[3-fluoro-4-(methyloxy)phenyl]pipeπdm-l-yl}carbonyl)-7-(2 -methyl- li/-benzimidazol-6-yl)-2,3,4, 5- tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["1 - { [7-(2-methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepin-4(5//)-yl] carbonyl} -4-phenylpipeπdin- 4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2 -methyl- li/-benzimidazol-6-yl)-4-[(4-propylpipendm-l -yl)carbonyl]-2,3,4,5-tetrahydro- 1 ,4-benzoxazeprne"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["8- { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -8- azabicyclo[3.2.1]octan-3-(endo)-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-{[4-(2,2-difluoroethyl)pipeπdm-l-yl]carbonyl}-7-(2-methyl-li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["8- { [7-(2-methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepm-4(5if)-yl] carbonyl} -8- azabicyclo[3.2.1]octan-3-one"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4- {[4-(difluoromethyl)pipeπdm-l-yl]carbonyl}-7-(2 -methyl- 177-benzimidazol-6-yl)-2, 3, 4, 5-tetrahydro- 1,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[(4-cyclopropylpipeπdin-l-yl)carbonyl]-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2 -methyl- li/-benzimidazol-6-yl)-4- {[2-(4-methylphenyl)pipeπdm- 1 -yl] carbonyl} -2,3,4,5-tetrahydro- 1 ,A- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-(8-azabicyclo[3.2.1]oct-8-ylcarbonyl)-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["2-(4-fluorophenyl)-l-({7-[4-(li/-imidazol-5-yl)phenyl]-2,3-dihydro-l,4-benzoxazepm-4(5i/)- yl} carbonyl)pipeπdm-4-one"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[(4-ethylpipendm-l-yl)carbonyl]-7-(2 -methyl- li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4-benzoxazepine methyl (6-{4-[(3-(endo)-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl)carbonyl]-2,3,4,5-tetrahydro-l,4- benzoxazepm-7-yl}-l//-benzimidazol-2-yl)carbamate"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["1 - { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -4-[3- (methyloxy)phenyl]piperidm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["1 - { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5//)-yl] carbonyl} -4-(3- methylphenyl)piperidm-4-ol \n\n 7-(2 -methyl- li/-benzimidazol-6-yl)-4- {[4-( 1 -methylethyl)pipeπdm- 1 -yl]carbonyl} -2,3 ,4,5-tetrahydro- 1 ,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-[4-(5-fluoro-l//-benzimidazol-2-yl)phenyl]-4-{[4-(tπfluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5- tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-{[2-(4-chloroplienyl)pipeπdin-l-yl]carbonyl}-7-(2-methyl-l/f-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4- { [4-(fluoromethyl)pipeπdm- 1 -yl] carbonyl} -7-(2-methyl- l//-benzimidazol-6-yl)-2,3 ,4,5-tetrahydro- 1,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["(±)-4- { [(25',4_R)-2,4-dimethylpipeπdin- 1 -yl] carbonyl} -7-(2 -methyl- l//-benzimidazol-6-yl)-2,3 ,4,5-tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["8- { [7-(2-methyl- l//-benzirmdazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -3 -[3- (tπfluoromethyl)phenyl] -8-azabicyclo[3.2.1 ]octan-3 -(endo)-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4- { [3 -(e«(io)-(fluoromethyl)-8-azabicyclo[3.2.1 ]oct- 8 -yl] carbonyl} -7-(2-methyl- l//-benzimidazol-6-yl)- 2,3,4,5-tetrahydro-l,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-{[4-(l,l-difluoroethyl)piperidm-l-yl]carbonyl}-7-(2-methyl-li/-benzimidazol-6-yl)-2,3,4,5-tetrahydro-l,4- benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["8-{[7-(2-ammo-li/-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}-3-methyl-8- azabicyclo[3.2.1]octan-3-(endo)-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-{[2-(4-chloro-3-fluorophenyl)pipeπdm-l-yl]carbonyl}-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5- tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["(±)-4-{[(25,45)-2,4-dimethylpipeπdm-l-yl]carbonyl}-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5-tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-[4-(5-fluoro-l//-benzimidazol-2-yl)phenyl]-4-{[4-(fluoromethyl)pipeπdm-l-yl]carbonyl}-2,3,4,5-tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["7-(2-methyl-li/-benzimidazol-6-yl)-4-[(l-phenyl-3,4-dihydroisoqumolm-2(l//)-yl)carbonyl]-2,3,4,5- tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["3-methyl-8-{[7-(2-methyl-l//-benzimidazol-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}-8- azabicyclo[3.2.1]octan-3-(endo)-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-(3 -fluorophenyl)- 1 - {[7-(2-methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepm-4(5//)- yl] carbonyl } pipeπdm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["1 - { [7-(2-methyl- l//-benzirmdazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -4- (trifluoromethyl)pipendm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[(3-fluoro-3-(e«ύ?o)-methyl-8-azabicyclo[3.2.1]oct-8-yl)carbonyl]-7-(2 -methyl- l//-benzimidazol-6-yl)- 2,3,4,5-tetrahydro-l,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-(2-fluorophenyl)- 1 - {[7-(2 -methyl- l//-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepm-4(5//)- yl] carbonyl } pipeπdm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-(3 -chlorophenyl)- 1 - {[7-(2 -methyl- li/-benzimidazol-6-yl)-2,3-dihydro- 1 ,4-benzoxazepm-4(577)- yl] carbonyl } pipeπdm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["8-{[7-(2-methyl-l/f-imidazo[4,5-b]pyridm-6-yl)-2,3-dihydro-l,4-benzoxazepm-4(5//)-yl]carbonyl}-3- (trifluoromethyl)-8-azabicyclo[3.2.1]octan-3-(endo)-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["4-[(3-(endo)-methyl-8-azabicyclo[3 2.1]oct-8-yl)carbonyl]-7-(2-methyl-l//-benzimidazol-6-yl)-2,3,4,5- tetrahydro- 1 ,4-benzoxazepme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["5- {4-[(4-methylpipeπdm- 1 -yl)carbonyl]-2,3,4,5-tetrahydro-l ,4-benzoxazepm-7-yl} - 1 ,3-thiazol-2-amme"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["1 - { [7-(2-methyl- l/f-benzimidazol-6-yl)-2,3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -4-[3- (trifluoromethyl)phenyl]pipendm-4-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["8- { [7-(2-methyl- l//-benzimidazol-6-yl)-2, 3 -dihydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -3 -(tπfluoromethyl)- 8-azabicyclo[3.2.1]octan-3-(endo)-ol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["5-(4- {[4-(tπfluoromethyl)pipeπdm- 1 -yl] carbonyl} -2,3 ,4,5-tetrahydro- 1 ,4-benzoxazepm-7-yl)- 1 ,3 -thiazol-2- amme, and"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["(±)-[(2R,4S)- 1 - { [7-(2 -methyl- l//-benzimidazol-6-yl)-2,3-dmydro- 1 ,4-benzoxazepm-4(5i/)-yl] carbonyl} -2- phenylpiperidm-4 -yl] methanol"],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["optionally as a pharmaceutically acceptable salt thereof."],"number":-1,"annotation":true,"title":false,"claim":false},{"lines":["A pharmaceutical composition which comprises a compound, optionally as pharmaceutically acceptable salt thereof, of Claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating a disease, disorder, or syndrome which method comprises administering to a patient a therapeutically effective amount of a compound of Claim 1, optionally as a pharmaceutically acceptable salt thereof, or administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 , optionally as a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 3 where the disease is cancer."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 4 where the cancer is breast cancer, mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK- transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervical cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, colon cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreatic cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, glioblastoma, or head and neck cancer."],"number":5,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}